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2. Abbreviations 
ACD  Allergic contact 
dermatitis 
 DNFB  Dinitrofluorobenzene 
ACN  Acetonitrile  DT  Diphtheria toxin 
AD   Atopic dermatitis  ELISA  Enzyme-linked 
immunosorbent assay 
AMP  Antimicrobial peptide  EGFP  Enhanced green 
fluorescent protein 
APC Antigen presenting cell  FBS  Fetal bovine serum 
API Asthma predictive index  FITC  Fluorescein 
isothiocyanate 
ATP  Adenosine triphosphate  FLG  Filaggrin 
BAL(F)  Bronchoalveolar lavage 
(fluid) 
 Foxp3 Forkhead box 3 
BCR  B cell receptor  GM-CSF Granulocyte 
macrophage colony-
stimulating factor 
BSA Bovine serum albumin  H&E Hematoxylin-eosin 
cAMP  Cyclic adenosine 
monophosphate 
 HDM  House dust mite 
CD Cluster of differentiation  HRP Horseradish peroxidase 
cDNA  Complementary 
deoxyribonucleic acid 
 IDEC  Inflammatory dendritic 
epidermal cell 
CHS  Contact hypersensitivity  IDO  Indoleamine-2,3-
dioxygenase 
CLA  Cutaneous lymphocyte 
associated antigen 
 IFN Interferon 
CTLA-4 Cytotoxic T-lymphocyte 
antigen 4 
 IHC  Immunohistochemistry 
DAMP Danger associated 
molecular pattern 
 IL Interleukin 
DC   Dendritic cell  IPEX  Immune dysregulation, 
polyendocrinopathy, 
enteropathy, X-linked 
DDC  Dermal dendritic cell  iTreg  Induced regulatory T 
cell 
DEREG  Depletion of regulatory T 
cells 
 LC  Langerhans cell 
dLN  Draining lymph node  LLNA  Local lymph node 
assay 
DNCB  Dinitrochlorobenzene  LN  Lymph node 
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MC  Mast cell  TEM  Effector memory T cell 
2-ME 2-mercaptoethanol  mRNA Messenger ribonucleic 
acid 
mDC  Myeoloid dendritic cell  Tfh  T follicular helper cell 
MEST  Mouse ear swelling test  TGF Transforming growth 
factor 
MHC  Major histocompatibility 
complex 
 Th  Helper T cell 
NK   Natural killer cell  TLR  Toll like receptor 
NTC No template control  TMA  Trimellitic anhydride 
nTreg  Natural regulatory T cell  TNCB  Trinitrochlorobenzene 
OVA  Ovalbumin  TNF Tumor necrosis factor 
OXA   4-ethoxymethylene-2-
phenyl-2-oxazolin-5-one 
(Oxazolone) 
 Treg   Regulatory T cell 
PAMP   Pathogen associated 
molecular pattern 
 TSLP Thymic stromal 
lymphopoietin 
PAS  Periodic acid Schiff  WAO  World Allergy 
Organization 
PBS  Phosphate buffered saline  WT  Wild type 
PCR  Polymerase chain 
reaction 
   
pDC  Plasmacytoid dendritic 
cell 
   
PMA  Phorbol-12-myristate-13-
acetate 
   
PRR   Pattern recognition 
receptor 
   
RORγt RAR-related orphan 
receptor γt 
   
RNA   Ribonucleic acid    
SAg Superantigen    
SEB  Staphylococcal 
enterotoxin B 
   
sLe(x) Sialyl Lewis X    
Tc  Cytotoxic T cell    
TCM  Central memory T cell    
TCR  T cell receptor    
Teff  Effector T cell    
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3. Abstract 
Atopic dermatitis (AD) is an allergic skin disease, characterized by relapsing eczema, dry 
skin and chronic skin inflammation. In some western countries, the prevalence of AD is as 
high as 20 % in children and 1-3 % in adults. A large proportion of AD patients also 
develop asthma later in life. Allergic contact dermatitis (ACD) in turn, is one of the 
leading occupational diseases worldwide, being responsible for a loss of work-time and 
demands for re-education. Therefore, allergic skin diseases not only impair the quality of 
life of patients but cause a great economical burden for the society. This thesis investigates 
some of the mechanisms behind allergic skin diseases with the help of experimental 
animal models.  
 
In an AD-model, an AD-like skin inflammation was induced by mechanical skin injury 
and epicutaneous sensitization. This induced a Th2 cytokine dominated inflammatory 
response at the site of allergen exposure, and elevation of allergy-related IgE antibody 
levels in the serum. The effects of skin colonizing bacteria Staphylococcus aureus derived 
enterotoxin B (SEB) were evaluated on the inflammatory response in AD-model. SEB 
application significantly exacerbated the allergen induced inflammatory response in the 
skin, increasing cellular infiltration, enhancing Th2 cytokine production and provoking 
Th1 cytokine production. Furthermore, SEB induced the production of SEB-specific IgE 
antibodies and enhanced the production of OVA-specific IgE antibodies. These results 
demonstrate that bacterial skin colonization may both augment the inflammatory response 
in AD patients and play a role in the chronification of the disease. 
 
Although regulatory T cells (Treg) are known to prevent allergic responses, their role in 
AD is still not clear. We utilized DEREG mice, in which the Foxp3+ Treg cells can be 
transiently depleted, to study the role of Foxp3+ Treg cells in the AD-like skin 
inflammation. The epidermal barrier in AD patients is often damaged by scratching or 
genetic defect. We observed that in the absence of Foxp3+ Treg cells, the skin injury alone 
induced a stronger inflammation compared with WT, indicating that Foxp3+ Treg cells are 
crucial in controlling skin injury induced inflammation. However, the addition of allergen 
further enhanced the inflammatory response and especially increased the production of 
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Th2 cytokines, suggesting that Foxp3+ cells are also essential in controlling the allergic 
responses in the skin. In addition, when allergen was administered into the lungs at a time 
point when the Treg compartment had been restored, the changes observed in the immune 
system during skin sensitization were readily transferred to the lungs. These results 
demonstrate that impaired Foxp3+ Treg function in AD patients may affect the asthma 
responses possibly developing later in these patients. 
 
In the ACD-model, the skin inflammation was induced by epicutaneous application of 
oxazolone in two phases: sensitization, when memory cells against the hapten were 
generated, but no clinical symptoms were observed, and elicitation, when the same hapten 
was applied on a site distant from the original sensitization site, resulting in a clinically 
observed inflammatory response. The role of Foxp3+ Treg cells was studied in these two 
phases and also in the clearance of the inflammation. The absence of Foxp3+ Treg cells in 
the sensitization phase dramatically exacerbated the skin inflammation, whereas the 
absence in the elicitation phase had no effect on the inflammatory response during the first 
24 hours post challenge. Instead, both depletions severely impaired the resolution of the 
inflammation, most likely due to the impaired ability of restored Foxp3+ Treg cells to 
accumulate in the skin. These results reveal that Foxp3+ Treg cells are crucial during the 
sensitization phase in the LNs and during the resolution phase in the skin. 
 
CCR4 is a chemokine receptor which together with chemokine receptor CCR10 is 
involved in lymphocyte trafficking into the skin. The ACD response was examined in 
CCR4 knock-out mice and surprisingly inflammation was exacerbated in these mice as 
compared with WT. Treg cell recruitment into the skin in these mice was comparable with 
the WT as was the chemotactic response of T cells towards CCR10 ligand CCL27. 
Instead, when the inflammatory response was followed at different time points after 
sensitization and challenge, increased proliferation of CD4+ cells was observed in   
CCR4-/- mice, indicating that CCR4 is somehow involved in the regulation of CD4+ cells 
during ACD responses. 
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4. Introduction 
In allergy, an exaggerated inflammatory response is mounted against a harmless 
substance. The prevalence of allergic diseases has been increasing for several decades and 
although may have reached a plateau in some industrialized countries, the incidence rate is 
still high (Latvala et al., 2005; Williams et al., 2008). The genetic background is of 
relevance in the onset of allergy e.g. it can cause impairment of the barrier integrity of 
epithelia or alternatively induce allergy related Th2 responses instead of more appropriate 
ones (Barnes, 2010). However, the rapid increase in the prevalence of allergy cannot be 
explained by genetic factors only, in other words the environment also plays a significant 
role (Williams et al., 2008). The so called 'hygiene hypothesis', one of the most widely 
accepted theories explaining the increase in the prevalence of allergy, states that 
diminished microbial burden due to improved hygiene, vaccinations and usage of 
antibiotics, has lead to unwanted immune responses such as allergies and autoimmunity 
(Okada et al., 2010). 
 
Atopic dermatitis (AD) is a chronic, inflammatory skin disease manifested by dry and 
itchy skin with relapsing eczematous skin lesions. The lesional skin is occupied by an 
increased numbers of cells of the immune system, such as eosinophils, mast cells and T 
cells. Moreover, these patients have elevated serum IgE levels. In the acute phase of the 
disease, Th2 type cytokines are produced while during the course of chronification, the 
response switches towards the Th1 type. AD also predisposes to so called "atopic march" 
since over 60 % of the AD patients develop food allergy, allergic rhinitis or asthma later in 
life (Bieber, 2010; Spergel, 2010).  
 
Another allergic skin disorder, allergic contact dermatitis (ACD), is one of the most 
common occupational diseases worldwide which induces loss of work-time and often is 
responsible for a need for change of occupation (Coenraads and Goncalo, 2007). In ACD, 
a small hapten that can be a chemical or metal, induces the formation of hapten-specific 
memory T cells, which upon re-exposure to the same hapten, mount an inflammatory 
response manifested by edema and erythema together with vesicle formation and oozing 
phenomena in the acute phase. In the chronic phase, the skin becomes lichenified and 
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cracked. Usually the symptoms appear within 24-96 hours post exposure at the site of 
hapten exposure although they can propagate to distant sites (Saint-Mezard et al., 2004).  
 
Asthma in turn, is a common chronic disorder of the airways characterized by airflow 
obstruction, bronchial hyperresponsiveness and underlying inflammation. There are 
several different types of asthma, but in allergic asthma, an inflammatory response and 
bronchoconstriction occurs in sensitized individuals when the allergen enters the airways 
(Lötvall et al., 2011). The development of allergic asthma can be associated with AD 
(Boguniewicz and Leung, 2010). 
 
Allergy can severely impair the quality of life and sometimes even leads to a life-
threatening condition, anaphylaxis. In addition, it poses a great financial burden on society 
due to the costs of therapy, sick leaves or re-training. Understanding the mechanisms that 
initiate and maintain an allergic response is essential for treatment and prevention of these 
diseases. The aim of this thesis was to unravel some of the mechanisms underlying the 
pathophysiology of skin related allergies. It was decided to investigate the consequences 
of bacterial colonisation on the inflammatory response in AD as well as the role of 
regulatory T cells (Treg) in the control of AD-like skin inflammation. In addition, the 
effects of Treg deficiency during skin sensitization on the subsequent development of 
airway inflammation were studied. The role of Treg cells in ACD was studied by 
depleting Treg cells during the different phases of an ACD response. The final study 
examined how the absence of a skin-homing chemokine receptor, CCR4, could affect the 
outcome of an ACD response. 
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5. Review of the literature 
5.1 Immunity 
5.1.1 Innate immunity 
Innate immunity represents the first line of defence of an immune response. In addition to 
epithelial surfaces, such as the skin or mucosal membranes, innate immunity comprises of 
antimicrobial peptides, plasma proteins and several different cell types, such as 
macrophages, neutrophils, eosinophils, mast cells, basophils, natural killer cells (NK), 
NKT cells and dendritic cells (DC). Epithelial surfaces form the physical and chemical 
barrier that prevents the pathogen from invading the body. For example, the protein-rich 
cells in the uppermost layer of the skin (epidermis) together with lipid-rich intercellular 
domains and junction proteins form a very dense layer which protects the body from the 
'outside' but also has other properties, e.g. preventing excess water leakage from the 
'inside' (Proksch et al., 2008). In addition, secretion of microbicidial substances inhibit 
microbial growth on epithelial surfaces and the presence of mucus in the airways, impairs 
the adherence of micro-organisms to the epithelium (Fritz et al., 2008; Metz and Maurer, 
2009; Parker and Prince, 2011). However, if a pathogen is able to breach the epithelial 
barrier it is taken up by phagocytic cells, macrophages, neutrophils or DCs. These cells 
recognize pathogen-associated molecular patterns (PAMP) common to many different 
pathogens, such as bacterial cell wall components or viral RNA through their pattern 
recognition receptors (PRR). In addition, they recognize danger associated molecular 
patterns (DAMPs), like heat-shock proteins, which are released in cases of tissue injury, 
and participate in the clearance of damaged or apoptotic host cells (Bianchi, 2007; Savina 
and Amigorena, 2007). 
 
Macrophages are present in large numbers in the tissues and they are usually the first cells 
to recognize an invading pathogen, a dying cell or a foreign substance. After recognition, 
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the target is internalized by phagocytosis and destroyed in intracellular vesicles called 
phagosomes via several mechanisms e.g. by major pH drop or production of lytic enzymes 
or free radicals. Macrophages also release cytokines and chemokines which recruit 
neutrophils, other leukocytes and complement proteins to the site of infection and activate 
them to initiate the process called inflammation (Mosser and Edwards, 2008; Stuart and 
Ezekowitz, 2005). Neutrophils participate in phagocytosis and may be even more efficient 
in the process than macrophages (Nordenfelt and Tapper, 2011). Complement is a series 
of proteins that are distributed in blood and tissues and work in a cascade to amplify the 
initial signal. Complement is activated by various self and non-self structures, such as 
apoptotic cells, immune complexes, bacterial lipopolysachharides and viral proteins. In a 
process called opsonization, complement proteins cover the pathogen, foreign substance or 
apoptotic cell, leading to its enhanced recognition and engulfment by phagocytes. 
Complement proteins also act as chemoattractants and activators for the leukocytes. In 
addition, complement proteins can form pores on the bacterial cell membrane, leading to 
their death (Kojouharova et al., 2010; Sjoberg et al., 2009; Wallis et al., 2010). NK cells 
recognize infected cells e.g. through altered host cell surface structures and they release 
proteins from their cytotoxic granules which induce apoptosis in the infected cells 
(Lunemann et al., 2009). Mast cells and eosinophils, in turn, target mainly extracellular 
pathogens. Upon activation they release preformed effector molecules such as histamine 
or eosinophilic peroxidase from their cytoplasmic granules. In addition, they synthesize 
and release inflammatory cytokines and chemokines (Kalesnikoff and Galli, 2008; Neves 
and Weller, 2009; Ryan and Fernando, 2009).  
 
Due to their destructive nature, innate immune responses are tightly controlled. For 
example, eosinophil numbers and activation are regulated at several levels, such as 
production of eosinophils by bone marrow, recruitment of eosinophils into the tissue or 
production of eosinophil activating cytokines. In allergy, this regulation is usually 
dysfunctional (Dombrowicz and Capron, 2001; Nissim Ben Efraim and Levi-Schaffer, 
2008). When an infectious agent has been removed, the inflammatory response is actively 
terminated. However, sometimes the inflammation becomes chronic, with persistent 
infiltration of leukocytes to the site of inflammation and production of inflammatory 
mediators (Serhan and Savill, 2005). This type of sustained inflammation is usually 
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detrimental to the host, e.g. by inducing tissue remodelling or fibrosis which impairs the 
normal function of the tissue (Galli and Tsai, 2008; Nissim Ben Efraim and Levi-Schaffer, 
2008). If an infection cannot be eliminated by innate defence mechanisms, an adaptive 
immune response is initiated by the cells of the innate immunity in a process called 
antigen presentation (Bonilla and Oettgen, 2010) 
 5.1.1.1 Antigen presentation  
Antigen presenting cells (APC) are highly specialized cells that activate the cells of the 
adaptive immune system. The main APCs are DCs, macrophages and B cells and of these, 
DCs are most important in presenting antigens to T cells and initiating adaptive immune 
responses (Itano and Jenkins, 2003). DCs are a heterogeneous group of different types of 
cells and they are divided into two main groups, plasmacytoid DCs (pDC) and myeloid 
DCs (mDC). Plasmacytoid DCs respond to the microbial stimulus, develop into type I 
interferon producing cells and are especially important during viral infections. These cells 
are capable of antigen-presenting but they are not as important in that process as mDCs.  
Myeloid DCs, instead, are efficient antigen-presenting cells and they are either tolerance-
inducing DCs or inflammatory DCs (Bieber et al., 2010; Itano and Jenkins, 2003). 
Immature DCs reside in the tissues or lymphoid organs (lymph nodes, spleen or mucosa-
associated lymphoid tissues). The recognition of a microbial component through PRR, or 
signals derived from cytokines produced during inflammation, induce DCs to take up 
antigens, process them and attach to the antigen-binding groove of MHC molecules. These 
MHC:peptide complexes are then delivered to the cell surface (Neefjes et al., 2011; 
Savina and Amigorena, 2007). Antigen engulfment induces a maturation process in DCs, 
during which they upregulate their expression of costimulatory molecules, downregulate 
antigen uptake and stabilize MHC:peptide complexes. At the same time, DCs in the 
tissues start to migrate towards the nearest lymph node (LN), where they present the 
antigen to T cells. T cells circulate between the blood and LNs and interact constantly with 
DCs in the LNs to screen for the presence of a specific antigen. If an antigen is not 
present, T cells exit the lymphoid organ, enter the bloodstream and continue to circulate. If 
an antigen is recognized, the T cell forms a more stable contact with the DC and becomes 
activated through signals driven by antigen recognition and costimulatory molecules 
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expressed on mature DCs. In addition, DC derived cytokines are needed to direct the 
differentiation of T cells (Curtsinger and Mescher, 2010; Itano and Jenkins, 2003; Marelli-
Berg et al., 2008).  
 5.1.1.2 DCs in the skin 
In the epidermal layer of the skin, a specialized subtype of DCs exists, called Langerhans 
cell (LC). LCs are recruited from the bone marrow as precursors during embryonic 
development, differentiate and then go through a proliferative burst early after birth, after 
which they replicate at a slow rate in the epidermis (Chorro et al., 2009; Vishwanath et al., 
2006). LCs are characterized by the presence of Birbeck granules (Birbeck et al., 1961), 
and the expression of langerin (CD207) (Valladeau et al., 2000). 
 
The dermis is occupied by dermal DCs (DDC). These can be langerin negative DCs that 
are either CD11b+ or CD11b- or langerin positive DCs that are either CD103+ or CD103- 
(Henri et al., 2010). In the absence of inflammation, both LCs and DDCs migrate from the 
skin to the draining LN (dLN) in order to maintain the tolerance to epidermal self-proteins 
(Bedoui et al., 2009; Steinman and Nussenzweig, 2002; Waithman et al., 2007). Although 
they express MHC molecules and costimulatory molecules, they do not produce IL-12 and 
thus do not activate T cells (Kissenpfennig et al., 2005; Stoitzner et al., 2005). In addition, 
both LCs and DDCs are able to provoke the generation of inducible regulatory T cells, a 
subtype of immunosuppressive cells (Guilliams et al., 2010; Loser et al., 2006). A subset 
of DDCs has been observed to activate memory T cells directly in the skin. At the same 
time, they activate regulatory T cells, most likely to inhibit excessive collateral damage to 
the skin (McLachlan et al., 2009).  
 
According to the Langerhans cell paradigm, LCs take up the antigens in the skin and 
migrate to the dLNs to present them to T cells in order to initiate adaptive immune 
responses. Recent advances in the field, however, have challenged this paradigm (Romani 
et al., 2010). For example, during inflammation, DDCs reach the dLNs faster than LCs, 
indicating that DDCs are able to initiate T cell responses (Kissenpfennig et al., 2005). In 
fact, in ACD, it appears that DDCs alone are sufficient to induce inflammation (Bennett et 
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al., 2005; Kissenpfennig et al., 2005), and in the absence of LCs, the inflammatory 
response can be even enhanced, pointing to a suppressive role for LCs in the skin (Bobr et 
al., 2010; Kaplan et al., 2005). However, LCs seem to be essential in inducing 
inflammation at low hapten doses or in situations where the antigen does not readily 
penetrate through the epidermis into the dermis (Kaplan et al., 2008; Wang et al., 2008). 
In addition, in some cases LCs are needed to transport antigens to dLNs, although the 
actual T-cell activation is achieved by LN residental DCs (Allan et al., 2006). 
 
Finally, another DC population, not found in the steady state, appears in the AD skin 
during inflammation. This subpopulation is called inflammatory dendritic epidermal cell 
(IDEC) and is characterized by expression of CD1alow, FcεRIhi and CD11bhi (Schuller et 
al., 2001; Wollenberg et al., 1996). In AD, IDECs invade the epidermis within 72 hours 
after the antigen challenge, and are sustained there also during the chronic state of the 
disease (Kerschenlohr et al., 2003). These cells express costimulatory molecules, CD80 
and CD86, in AD lesions, and they induce naive T cells to produce IFN-γ upon priming, 
suggesting that IDECs may play a role in the chronification of AD (Novak et al., 2004b; 
Schuller et al., 2001). 
5.1.2 Adaptive Immunity 
The adaptive immunity is responsible for antigen-specific immune responses and is 
mediated by lymphocytes, namely T cells and B cells. These cells recognize unique 
structural motifs, called antigens, through T cell (TCR) or B cell receptors (BCR), 
respectively. One cell carries receptors specific for one antigen and after recognition of 
their specific antigen, these cells become activated and start to exert their effector 
functions. B-cells produce antigen-specific antibodies, whereas T cells either kill infected 
cells or enhance the effector activity of other leukocytes. Adaptive immunity utilizes many 
of the same effector mechanisms as innate immunity, e.g. antibodies enhance the 
engulfment and destroyal of the pathogen by phagocytes. Whereas the innate immune 
responses do not evolve and always mount a similar kind of response upon subsequent 
encounters with the same antigen, T and B cells go through series of TCR and BCR 
rearrangements to improve their antigen specificities. In addition, long-lived memory cells 
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are generated with the first contact with the antigen, and these memory cells then respond 
rapidly when recognizing their cognate antigen upon re-infection. During these secondary 
infections, the infective agent is usually cleared before any disease symptoms are observed 
(Bonilla and Oettgen, 2010).  
 
Like the innate immunity responses, adaptive immunity also needs to be carefully 
controlled. During T cell development in the thymus, highly self-reactive T cells are 
deleted. However, sometimes this elimination fails and in addition, T cells responding 
only weakly or intermediately to self structures may escape thymic selection. The activity 
of these cells needs to be inhibited in the periphery in order to prevent their reactivity 
against self structures and the induction of autoimmunity. This is achieved through the 
induction of a state of unresponsiveness, anergy, in these cells, deletion of the cells or 
active suppression of their function. Some of the self-antigen recognizing clones 
differentiate into regulatory T cells with immunosuppressive properties (Jiang and Chess, 
2009; Pacholczyk and Kern, 2008). B cells also go through negative selection, during 
which the self reactive clones either undergo receptor rearrangements, deletion or 
induction of anergy (Grimaldi et al., 2005). Another kind of unwanted adaptive immune 
response is generated when lymphocytes mount an immune response against harmless 
antigens such as food proteins or pollen. This results in the development of 
hypersensitivity and it will be discussed in more detail later.  
 5.1.2.1 T cells 
T cells develop in the thymus after which they circulate between secondary lymphoid 
tissues and blood (Butcher and Picker, 1996). These cells are divided into two main 
groups, cytotoxic T cells (Tc) and helper T cells (Th). Tc cells express a surface marker 
CD8 and recognize antigens bound to the MHCI molecule which is expressed on the 
surface of almost all eukaryotic cells of the body. Th cells bear a surface marker CD4 and 
recognize antigens bound to MHCII molecules (Zamoyska, 1998). T cells that have never 
encountered their antigen are called naive T cells. The first contact with a specific antigen 
results in the activation of a naive T cell, which starts to proliferate and differentiate into 
effector T cell (Teff). This process is called priming. After several days of differentiation 
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and proliferation, an event known as clonal expansion, Teff cells enter the bloodstream 
and migrate into the site of infection. A Teff cell is then able to respond quickly when 
recognizes the same antigen on other cells without the need for co-stimulation (Bousso, 
2008; Croft et al., 1994)  
 
Tc cells are important in the defence against intracellular pathogens, especially viruses. 
Once activated, they induce apoptosis of the cells bearing the antigen. Apoptosis is 
achieved either by the release of preformed effector molecules, such as perforin, or 
through Fas-Fas ligand (FasL) interactions (Barry and Bleackley, 2002). In addition, Tc 
cells produce inflammatory cytokines, which can have various effects on the inflammatory 
response (Cerwenka et al., 1998). Virus-infected APCs can activate CD8 cells directly in 
some cases, but most often additional help from Th cells is needed, especially during 
secondary responses (Bennett et al., 1997; Buller et al., 1987; Janssen et al., 2003). 
 
In some situations Th cells can be cytotoxic (Appay et al., 2002), but mostly they help B 
cells to produce antibodies, activate Tc cells or infected macrophages and enhance 
neutrophil responses (Schepers et al., 2005). Th cells differentiate into various subsets, or 
lineages, distinguished by the cytokines they produce upon activation (Table 1). 
Development into a certain subtype depends on several factors, such as the type and dose 
of antigen, route of antigen delivery and the microenvironment during and before antigen 
presentation. The currently recognized effector Th lineages are Th1, Th2, and Th17. In 
addition, regulatory T cell (Treg) subtypes exist, which are involved in suppressing 
immune responses and will be discussed in a separate chapter below. Th9, Th22 and Tfh 
have been proposed to be potential new Th cell lineages, but since the cytokines they 
produce are produced also by Th1/Th2/Th17/Treg cells and no unique transcription factors 
have been described for these cells, it is possible that these lineages are subtypes of the 
four main lineages (Akdis et al., 2011; Veldhoen, 2009; Zhu and Paul, 2010). 
 
Th1 cells develop in the presence of IL-12 and IFN-γ, produce IFN-γ and are mainly 
targeting immune responses against intracellular pathogens. T-bet is a specific 
transcription factor for Th1 lineage. Instead, Th2 cells develop in the presence of IL-4, to 
produce IL-4, IL-5 and IL-13, express transcription factor GATA-3 and are necessary for 
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mounting immunity against extracellular pathogens. In allergy, Th2 cells dominate and 
Th2 cytokines, IL-4 and IL-13, induce the class switching to IgE in B cells. Th17 cell are 
generated in the presence of TGF-β, IL-6, IL-21 and IL-23, and produce IL-17A, IL-17F, 
IL-6, IL-8, TNF-α, IL-22 and IL-26. They are needed for immunity against extracellular 
pathogens and are involved in some autoimmune diseases. Some Th17 responses have 
been reported in allergies as well. RORγT is a Th17 lineage specific transcription factor. 
The possible Th9 lineage development is driven by IL-4 in the presence of TGF-β, leading 
to the production of IL-9 and IL-10. Th9 cells play a role in mucus production and tissue 
inflammation. Th22 cells need TNF-α and IL-6 for development, produce IL-22 and are 
involved in tissue inflammation. The development of T-follicular helper cells (Tfh) is 
induced by IL-21, which they also produce and these cells are needed to help B cells in 
antibody production (Akdis et al., 2011; Veldhoen, 2009; Zhu and Paul, 2010).  
 
During the first contact with the antigen, memory T cells are generated. They are long-
lived cells, which mount a rapid immune response upon subsequent challenges with the 
same antigen, due to lowered threshold for activation. For example, lower antigen doses 
and various types of APCs, such as B cells, macrophages or endothelial cells are able to 
activate memory T cells (Bushar and Farber, 2008). Originally, memory cells were 
divided into two main subsets, central memory T cells (TCM) that express CCR7 and then 
target and home in on lymph nodes and effector memory T cells (TEM) which do not 
express CCR7 and thus lose the ability to return to LNs, and circulate between blood and 
tissue. TEM cells are able to enter the tissues and rapidly evoke inflammatory reactions in 
response to pathogens. Instead, TCM cells home in on the lymphoid tissue and upon 
antigen recognition, stimulate B cells and generate new Teff cells (Sallusto et al., 1999). 
Nowadays it is recognized however, that both subsets are equally capable of exerting 
effector functions and that memory T cells may express a vast variety of different homing 
receptors (Bushar and Farber, 2008). 
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Table 1 Different Th cell lineages, cytokines needed for their differentiation, specific 
transcription factors, cytokines produced upon activation and the main effector functions 
of different lineages. 
 T cell 
lineage 
Inducing 
cytokines 
Lineage 
specific 
transcription 
factor 
Cytokines 
produced 
upon 
activation 
Effector functions
Th1 IL-12, 
IFN-γ 
Tbet IFN-γ Intracellular 
pathogens, 
apoptosis of tissue 
cells, autoimmune 
diseases 
Th2 IL-4 GATA-3 IL-4, IL-5, 
IL-13 
Extracellular 
parasites, allergic 
inflammation 
Th17 IL-6, 
TGF-β, 
IL-21,   
IL-23 
RORγT IL-6, IL-8, 
IL-17A,     
IL-17F,      
IL-22, IL-26 
Extracellular 
bacteria and fungi, 
autoimmune 
diseases 
nTreg IL-2 or 
IL-15, 
(TGF-β) 
Foxp3 TGF-β, IL-10 Immune 
homeostasis, 
control of 
inflammation 
Confirmed 
lineages 
Foxp3+ 
iTreg 
IL-2, 
TGF-β 
Foxp3 TGF-β, IL-10 Immune 
homeostasis, 
control of 
inflammation 
Th9 IL-4, 
TGF-β 
 IL-9 Mucus production, 
tissue 
inflammation 
Th22 TNF-α, 
IL-6 
 IL-22 Tissue 
inflammation 
Tfh IL-21  IL-21 Antibody synthesis
Th3 TGF-β, 
IL-4,  
IL-10 
 TGF-β Oral tolerance 
Potential 
new lineages 
Tr1 IL-10  IL-10 Immune 
suppression 
References: (Akdis et al., 2011; Curotto de Lafaille and Lafaille, 2009; Roncarolo et al., 
2006; Weiner, 2001; Veldhoen, 2009; Zhu and Paul, 2010) 
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 5.1.2.2 Regulatory T cells 
Regulatory T cells (Treg) control immune homeostasis (Fontenot et al., 2003; Hori et al., 
2003), prevent autoimmunity (Sakaguchi et al., 1995), suppress allergic responses 
(Karlsson et al., 2004; Ling et al., 2004), control immune responses against pathogens 
(Hesse et al., 2004; Powrie et al., 2003) and participate in the resolution of inflammation 
(Kearley et al., 2005; Leech et al., 2007). Treg cells can be roughly divided into two 
groups: natural Treg cells (nTreg) and induced Treg cells (iTreg). Natural Treg cells 
develop in the thymus, represent 10-15 % of the CD4+ T cells and although they are 
thought to mainly suppress self-reactive T cells (Hsieh et al., 2004; Sakaguchi et al., 
1995), they are able to recognize pathogen derived antigens and proliferate upon antigen 
encounter (Suffia et al., 2006). Natural Treg cells express many surface markers e.g. 
CD25 (Sakaguchi et al., 1995), CTLA-4 (Kingsley et al., 2002), GITR (Shimizu et al., 
2002), OX40 (Takeda et al., 2004), CD39, CD73 (Deaglio et al., 2007) and folate receptor 
4 (Yamaguchi et al., 2007)  in addition to transcription factor Foxp3, which is essential for 
their function and development (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 
2003). However, neither of these markers is strictly specific for nTreg cells in humans, 
since they can be transiently expressed also by activated Teff cells. In mouse, instead, 
Foxp3 is expressed exclusively by Treg cells (Belkaid, 2007; Vignali et al., 2008; Ziegler, 
2006). 
 
Induced Treg cells develop in the periphery from naive T cells e.g. in response to 
superantigen exposure or subimmunogenic doses of antigen (Apostolou and von Boehmer, 
2004; Grundstrom et al., 2003; Kretschmer et al., 2005). Some, but not all iTreg cells 
express the transcription factor Foxp3 (Chen et al., 2003; Stock et al., 2004; Vieira et al., 
2004). The inducible Treg cells include Foxp3- IL-10 producing Tr1 cells, Foxp3- TGF-β 
producing Th3 cells and Treg cells that are converted into Foxp3+ in the context of 
infection (Belkaid, 2007; Vignali et al., 2008). In vitro, the generation of iTreg cells is 
achieved through TCR engagement of naive T cells in the presence of TGF-β (Chen et al., 
2003; Fantini et al., 2004; Park et al., 2004). Interestingly, also fully differentiated 
memory T cells can be converted into Foxp3 expressing Treg cells in the presence of 
TGF-β, α-IL-4, α-IFN-γ, as well as retinoic acid, which is a booster of TGF-β signaling 
and rapamycin, an enhancer of Treg expansion (Kim et al., 2010).  
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In humans, mutations in the Foxp3 gene result in a fatal lymphoproliferative disease called 
IPEX (immune dysregulation, polyendocrinopathy, enteropathy, X-linked). Patients with 
IPEX suffer from severe autoimmune conditions as well as food allergies, persistent 
eczema and they have elevated serum IgE levels (Bennett et al., 2001). Similar effects are 
observed in mouse with deficient or attenuated Foxp3 protein expression (Lin et al., 2005; 
Wan and Flavell, 2007). Although essential for the function of the immune system, Treg 
cells can also be harmful by preventing immune responses against tumours or pathogens 
(Curiel et al., 2004; Hisaeda et al., 2004; Taylor et al., 2005; Walther et al., 2005) or by 
hindering efficient immunisation after vaccination (Moore et al., 2005; Toka et al., 2004). 
 
Treg cells utilize multiple different mechanisms by which they suppress immune cells 
(Fig. 1). They exert suppressive functions both at lymphoid organs as well as at the site of 
inflammation and the molecular mechanisms of suppression may differ depending on the 
localization of the Treg cells. Treg cells can suppress Teff cells either directly or through 
actions on DCs (Tang and Bluestone, 2008).  
 
One important mechanism of Teff targeted suppression is the production of suppressive 
cytokines IL-10, TGF-β and IL-35 by Treg cells (Asseman et al., 1999; Collison et al., 
2007; Nakamura et al., 2001). Treg cells can also kill Teff cells through secretion of 
cytolytic enzymes such as perforin or granzyme A and B (Cao et al., 2007; Gondek et al., 
2005; Grossman et al., 2004).  
 
IL-2 is an important cytokine for the proliferation and consumption of IL-2 through the 
CD25 receptor present on Treg cells has been considered to suppress proliferation of Teff 
cells (Pandiyan et al., 2007; Scheffold et al., 2005). However, a recent experiment by Tran 
et al. suggests that this is not a major mechanism of suppression. Their experiments 
utilized either human Treg cells together with mouse Teff cells or vice versa and they 
noted that human Treg cells were equally suppressive either with a functional CD25 
receptor or its blocked counterpart. On the other hand, mouse Treg cells were not able to 
suppress human responder cells although mouse Treg cells were capable of binding human 
IL-2, thus depriving human cells of IL-2 (Tran et al., 2009). Instead, Treg cells were able 
to downregulate the expression of IL-2 in Teff cells (Oberle et al., 2007; Thornton and 
Shevach, 1998). One mechanism to achieve this, is the transfer of cyclic adenosine 
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monophosphate (cAMP), a potent inhibitor of IL-2 synthesis and T cell proliferation, into 
Teff cells via gap junctions (Bopp et al., 2007). The absence of functional galectin-1 or 
OX40 from Treg cells impairs their ability to suppress Teff cell proliferation in vitro 
(Garin et al., 2007; Takeda et al., 2004) indicating a role for these molecules in the control 
of Teff cell activation and/or proliferation. 
 
Treg cells are also able to interfere with the maturation and/or function of DCs. CTLA-4- 
CD80/86 interactions between Treg cells and DCs induce the production of Indoleamine-
2,3-dioxygenase (IDO) from DCs. IDO catabolizes tryptophan into a toxic metabolite, 
which suppresses Teff cell functions (Fallarino et al., 2003). In addition, the CTLA-4-
CD80/86 interaction leads to downregulation of two costimulatory molecules, CD80 and 
CD86, on APC and the subsequent decline in the activation of Teff cells (Cederbom et al., 
2000; Onishi et al., 2008; Wing et al., 2008). Similarly, fibrinogen-like protein 2 (FGL2)-
FcγRIIB or LAG3-MHCII interactions between Treg cells and DCs, sustains DCs in their 
immature state (Liang et al., 2008; Shalev et al., 2008). IL-10 production, in turn, 
potentially interferes with the production of proinflammatory cytokines from DCs (Houot 
et al., 2006). Treg cells are also able to eliminate DCs through Fas-FasL interactions 
(Gorbachev and Fairchild, 2010; Stranges et al., 2007). 
 
Treg cells inhibit stable contacts between Teff cells and APCs and in that way interfere 
with Teff cell activation (Tadokoro et al., 2006). For example, in the absence of a 
proinflammatory stimulus, Treg cells undergo prolonged interactions with immature DCs 
through neuropilin (Nrp-1) expressed on Treg cells and this phenomenon possibly 
overrides the binding of naive Th cells with the same specificity (Sarris et al., 2008). 
 
Treg cells can cleave the endogenous danger signal, ATP, into immunosuppressive 
adenosine through actions of ectoenzymes CD39 and CD73 on the surface of Treg cells 
(Borsellino et al., 2007; Deaglio et al., 2007; Kobie et al., 2006). ATP drives the 
maturation of DCs (Schnurr et al., 2000) and cleavage of ATP removes this 
immunostimulatory agent from the environment. In addition, the cleavage product, 
adenosine, inhibits Teff cell functions, enhances the formation of iTreg cells and 
downregulates the expression of E- and P-selectin on endothelium, impairing the 
 
 
 
 
24
recruitment of Teff cells into the tissue (Ring et al., 2009; Zarek et al., 2008). Treg cells 
can also have effects on other cells of the immune system, e.g. OX40-OX40L interactions 
between Treg cells and mast cells suppress IgE-induced activation of mast cells (Gri et al., 
2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Main mechanisms of Treg mediated suppression. Treg cells suppress Teff cells 
 directly or via DCs. Mechanisms targeted at Teff cells directly include production of 
 inhibitory cytokines, cytolysis through release of cytolytic enzymes, metabolic 
 disruption including secretion of galectin-1 or transfer of cAMP through gap 
 junctions. Galectin-1 and cAMP interfere with IL-2 production in Teff cells. 
 Ectoenzymes CD39 and CD73 convert ATP into adenosine with various 
 immunosuppressive effects. Mechanisms mediated through DCs involve sustaining 
 DCs in their immature state e.g. through FLG2/FcγRIIB or LAG-3/MHCII 
 interactions. The secretion of IL-10 potentially inhibits the production of 
 inflammatory cytokines from DCs. Interactions between CTLA-4 on Treg cells and 
 CD80 or CD86 on DCs, downregulate the expression of these costimulatory 
 molecules and induce the production of IDO which catabolizes tryptophan into an 
 immunosuppressive metabolite. Fas-FasL interactions induce apoptosis of DCs 
 (Garin et al., 2007; Gorbachev and Fairchild, 2010; Houot et al., 2006; Shalev et al., 
 2008; Stranges et al., 2007; Tran et al., 2009; Vignali et al., 2008) 
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The general view is that Treg activation requires stimulation through an antigen receptor 
(Thornton and Shevach, 2000), although there are some recent reports which indicate that 
Treg cells can be suppressive even in the absence of specific antigen or can be activated 
by ATP (Ring et al., 2010; Szymczak-Workman et al., 2009; Tomura et al., 2010). 
Nevertheless, antigen-specific Treg cells in some instances seem to be more effective in 
suppression than antigen non-specific cells (Tomura et al., 2010; Zuany-Amorim et al., 
2002) and at least in the case of Foxp3+ iTreg cells, antigen stimulation is needed to 
generate and maintain these cells (Haribhai et al., 2011). Once activated, Treg cells do not 
require further stimulation through TCR and they are able to suppress any cell nearby, also 
cells with different antigen specificities, through a mechanism called bystander 
suppression (Shevach, 2009; Szymczak-Workman et al., 2009; Thornton and Shevach, 
2000). In addition to natural and inducible Treg cells, subsets of CD8+ T cells, IL-10 
producing NK T cells, CD4-CD8- T cells or γδ T cells may have regulatory functions and 
participate in the suppression of immune responses (Tang and Bluestone, 2008). 
 5.1.2.3 B cells and IgE 
B cells are responsible for the production of antibodies, which in turn bind to and 
neutralize pathogens or facilitate their removal by phagocytic cells. B cells develop in the 
bone marrow and, like T cells, circulate between different lymphoid organs in search for a 
specific antigen. Binding of an antigen into a B cell receptor, induces the internalization 
and processing of the antigen and finally presentation to a Th cell, which has also become 
activated by the same antigen. The cytokines produced by activated Th cells and co-
stimulatory molecules on their surface induce proliferation of B cells and promote their 
differentiation into antibody producing plasma cells or memory B cells (Bonilla and 
Oettgen, 2010; Burton and Oettgen, 2011; Harwood and Batista, 2010; Tangye et al., 
2012). Some antigens, such as plant lectins, can activate B cells directly, without the help 
of T cells. In addition, long polysaccharide chains with repeating molecular patterns may 
cross-link the immunoglobulin receptors on the cell surface and together with DC derived 
signals induce T cell -independent activation of B cells (Bonilla and Oettgen, 2010).  
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One B cell clone is able to produce antibodies of only one specificity, the same as the B 
cell receptor they express on their surface. Antibodies can be of different isotype, IgM, 
IgG, IgA, IgE or IgD, and each has own specific effector functions. When a B cell is first 
activated, it starts to produce the IgM isotype and to some extent IgD, but upon maturation 
and signals derived from Th cells, changes the isotype in a process called class-switching. 
IgG is the most common isotype, and has four distinct subtypes in human (IgG1, IgG2, 
IgG3 and IgG4) and mouse (IgG1, IgG2a, IgG2b, IgG3). IgA is an important secreted 
isotype in the epithelium of the intestinal and respiratory tracts, and has two subtypes in 
humans, IgA1 and IgA2 (Chen and Cerutti, 2010; Stavnezer, 1996). The function and 
relevance of IgD are unclear, but it has been shown that neutrophils and eosinophils can 
bind significant levels of IgD under certain pathological conditions, such as skin allergy 
and inflammation, and IgD has been found to be the predominant Ig class present on 
neutrophils in patients with ACD. Moreover, IgD may act as a chemotactic agent for 
neutrophils and eosinophils during ACD (Chen and Cerutti, 2010). 
 
IgE activates mast cells, basophils and eosinophils and plays an important role in the 
pathomechanisms of allergy. In contrast to the other antibodies, only some of the IgE can 
be found in the circulation where it is bound to the surface of basophils, eosinophils or 
circulating monocytes. Most of the IgE is localized in the tissues, bound to mast cells 
through high affinity receptor FcεRI. In addition, APCs such as dendritic cells and 
Langerhans cells express FcεRI and bind IgE antibodies (Johansson, 2011; Novak et al., 
2003). Production of IgE first requires development of Th2 cells from naive T cells, after 
which Th derived cytokines, IL-4 and IL-13 and costimulatory signals, such as CD40L, 
induce the class switching into IgE (Oettgen, 2000). Some individuals are genetically 
more prone to develop Th2 biased responses and IgE production (Brown and McLean, 
2009) and certain antigenic determinants, small antigen doses or the routes of antigen 
presentation may favour IgE production. Since IgE is thought to originally have developed 
to provide immunity against parasites, Th2 polarization is usually favoured at sites 
common for parasite entry, such as skin or mucosa-associated lymphoid tissues of airways 
and gut (Bannon and Ogawa, 2006; Nelde et al., 2001; Rajan, 2003). 
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5.1.3 Cytokines  
Cytokines are small proteins released by cells usually in response to a particular activating 
signal. Cytokines can act in an autocrine, paracrine or endocrine manner by binding to 
specific receptors on the surface of responder cells. Cytokines are a structurally diverse 
group of molecules and cytokine induced signalling provokes various responses in 
responding cells. As discussed earlier, Th cells can be divided into different subsets based 
on the cytokines they produce upon activation. Some cytokines such as IL-1 and TNF-α 
are considered as pro-inflammatory, since they strongly promote inflammatory responses, 
while other cytokines, like IL-10 and TGF-β, are anti-inflammatory and participate in the 
suppression or prevention of immune responses (Dinarello, 2000). However, depending on 
the context in which the cytokine is produced, or the cell type that responds to the 
cytokine, the same cytokine can possess both pro-inflammatory and anti-inflammatory 
properties. For example, TGF-β is needed for the induction of immunosuppressive iTreg 
cells and the maintenance of nTreg cells, but in the presence of IL-6, TGF-β promotes the 
development of Th17 cells. These cells participate in the inflammatory reactions as 
effector cells and may promote autoimmunity. A similar kind of pleiotropic role has been 
described also for IL-10 and IL-22 (Sanjabi et al., 2009). 
 
In terms of allergy, Th2 cytokines are especially important. These include IL-4, IL-5 and 
IL-13 which promote IgE production, suppress Th1 responses, enhance Th2 development 
and affect eosinophil recruitment and survival. The expression of these cytokines is 
upregulated during allergy (Akdis et al., 2011). In recent years, several other cytokines 
have also been shown to participate in allergic inflammation. For example, IL-25 is 
produced by Th2 cells, activated eosinophils and basophils and it enhances the production 
of Th2 cytokines and increases eosinophil survival and their expression of adhesion 
molecules (Cheung et al., 2006; Fort et al., 2001; Wang et al., 2007b). Furthermore, IL-25 
can inhibit filaggrin synthesis, an important molecule for skin barrier function. In AD 
patients, IL-25 is produced by dermal DCs, and may thus influence the pathophysiology of 
AD both by augmenting Th2 responses and impairing the barrier function of the skin 
(Hvid et al., 2011).   
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IL-31 is expressed by activated Th cells, especially of Th2 subtype and expression is 
upregulated in AD and ACD patients (Bilsborough et al., 2006; Neis et al., 2006). 
Furthermore, IL-31 is strongly associated with pruritus accompanying atopic lesions and 
may therefore augment the inflammatory response by inducing scratching, which then 
leads to further damage of the skin barrier (Dillon et al., 2004; Sonkoly et al., 2006). 
      
IL-33, in turn, signals through receptor ST2 and induces or enhances the production of 
Th2 cytokines both in vivo and in vitro (Schmitz et al., 2005). Increased numbers of IL-33 
positive epithelial cells has been detected in AD patients (Pushparaj et al., 2009).   
 
Although allergic reactions are generally considered to be Th2 mediated, also other 
cytokines play an important role. For example, in ACD, mice deficient of IFN-γ or IFN-γ 
receptor demonstrate strongly diminished ACD responses (Wakabayashi et al., 2005). 
Attenuated CHS responses are also observed in mice treated with neutralizing antibodies 
against IL-17 (He et al., 2006)  and increased levels of IL-17A have been reported in AD 
as well (Toda et al., 2003). Furthermore, elevated levels of IL-22 producing CD4+ and 
CD8+ cells have been detected in the AD lesions and their numbers correlate with the 
disease severity (Nograles et al., 2009). Increased numbers of IL-22+ T cells in the serum 
have been reported both in AD and in ACD (Eyerich et al., 2009). In addition to above 
mentioned cytokines, several other cytokines, such as IL-3, IL-6, IL-9, IL-15, IL-18, IL-19 
and IL-20, may participate in the development of Th2 biased responses by several 
mechanisms, like activating mast cells and eosinophils, suppressing Treg cells, enhancing 
the differentiation of Th2 cells and downregulating Th1 responses (Akdis et al., 2011). 
 
5.1.4 Chemokines 
Chemokines are cytokines which act as chemoattractants. In a similar manner to 
cytokines, chemokines bind to specific receptors and different cell types express different 
kind of receptors. Some chemokines are expressed in the absence of any specific stimulus 
and are termed 'homeostatic' whereas the expression of other chemokines is induced upon 
activation. These chemokines belong to the 'inflammatory' class. Depending on the 
chemokines produced at the site of inflammation, certain types of cells are recruited. At 
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the moment, at least 48 different chemokines have been identified and they are divided 
into different subclasses based on the cysteine residue composition near the N-terminal 
end of the corresponding chemokine. CC-chemokines have two adjacent cysteine residues, 
while CXC-chemokines have their cysteine residues separated by one amino acid. In 
addition to these two main classes, there are two members in the C-chemokine family 
which have only one cysteine residue, and one chemokine in the CX3CL - chemokine 
family, in which the cysteine residues are separated by three amino acids. Chemokine 
receptors are G-protein coupled seven-span transmembrane proteins. CC class chemokines 
bind to CC-receptors, of which ten are known at the moment and are designated as CCR1-
10. CXC chemokines bind to CXC receptors, designated as CXCR1-7. C-chemokines bind 
to receptor XCR1 and CX3CL chemokine to receptor CX3CR1 (Zlotnik et al., 2006).  
 
Chemokines can be released by several different cell types but they act mainly on 
leukocytes. The role of chemokines in cell recruitment involves two different stages: first, 
they trigger conformational changes in the integrins expressed on leukocytes as they roll 
along endothelium. These changes cause the rolling cells to stop and to adhere firmly to 
the endothelium. Second, once they have been extravasated into the tissue, leukocytes are 
guided to the site of inflammation by a chemotactic gradient formed by chemokines 
(Middleton et al., 2002). In addition to participating in recruitment of inflammatory cells, 
chemokines are also involved in the leukocyte development and activation as well as 
angiogenesis (Ono et al., 2003; Rosenkilde and Schwartz, 2004). 
 
There are many chemokines that are of special importance during allergic skin responses. 
For example CCL11, CCL24 and CCL26, also known as eotaxins, are involved in the 
recruitment of eosinophils (Owczarek et al., 2010). CCL17, CCL22 and CCL27 (Homey 
et al., 2002; Horikawa et al., 2002; Kusumoto et al., 2007), in turn, are essential for T cell 
homing into the skin (in more detail below). CXCL9 and CXCL10 are detected in the skin 
during ACD responses and participate in the T cell and monocyte recruitment (Vocanson 
et al., 2009). CCL1 is expressed on atopic lesions and is involved in the accumulation of 
memory T cells and LCs into the skin (Gombert et al., 2005). 
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 5.1.4.1 Skin-homing chemokine recptors and CLA  
CCR4 and CCR10 are two important chemokine receptors with regard to the homing of T 
cells into skin during skin inflammation. The absence of only one of these receptors can 
lead to diminished inflammatory responses in the skin (Campbell et al., 2007; Homey et 
al., 2002). However, CCR4 and CCR10 seem to have also overlapping functions since in 
some situations, the lack of one receptor can be compensated by the other and only 
simultaneous blockade of both receptors leads to impaired recruitment of inflammatory 
cells into the skin (Mirshahpanah et al., 2008; Reiss et al., 2001; Wang et al., 2009b).  
 
CCR4 is mainly expressed by Th2 cells (Bonecchi et al., 1998; Imai et al., 1999), 
although also other cell types, such as platelets and basophils have been reported to 
express CCR4 (Power et al., 1995a; Power et al., 1995b). In addition, Treg cells express 
CCR4 (Iellem et al., 2001) this being essential for efficient Treg entry into the skin in the 
steady state (Sather et al., 2007). In some inflammatory situations, CCR4 is also needed 
for Treg cell homing or retention in the lymph nodes and efficient regulatory function 
(Yuan et al., 2007). 
 
CCL17 and CCL22 are two ligands for CCR4 (Godiska et al., 1997; Imai et al., 1997; 
Imai et al., 1998). CCL17 is expressed by activated dermal DCs and cutaneous venules, 
where it is further upregulated during inflammation (Alferink et al., 2003; Campbell et al., 
1999). DCs produce CCL22 upon maturation (Nagorsen et al., 2004) and neutralization of 
CCL22 or blockade of CCR4 receptor greatly impairs the formation of stable contacts 
between DCs and T cells, pointing to an important role for CCL22-CCR4 interaction in T 
cell activation (Wu et al., 2001).  
 
The expressions of CCL17 and CCL22 are upregulated in the skin during experimental 
ACD (Kusumoto et al., 2007). In AD patients, CCL17 levels are elevated in the serum, 
and the extent of the increase correlates with the severity of the disease (Saeki and 
Tamaki, 2006; Shimada et al., 2004). In addition, monocyte derived DCs from AD 
patients produce more CCL22 than healthy controls (Hashimoto et al., 2006). 
Inflammatory responses are attenuated in CCL17 deficient mice, both in ACD and AD 
models (Alferink et al., 2003; Stutte et al., 2010).  
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CCR10 receptor has also two ligands, CCL27 and CCL28 (Homey et al., 2000; Wang et 
al., 2000b). CCR10 expression has been detected in most of the T cells infiltrating 
inflamed skin in AD, ACD and psoriasis, and neutralization of CCR10-CCL27 
interactions lead to impaired homing of T cells into the skin during allergen-induced skin 
inflammation (Homey et al., 2002). CCL27 is constitutively expressed by keratinocytes 
but is also associated with skin inflammation. In addition, CCL27 has been shown to 
attract skin homing cutaneous lymphocyte associated antigen (CLA) positive cells in vitro 
(Morales et al., 1999). CCL28 mRNA expression has been observed in the normal gut and 
lungs, but also in the context of inflammation (Wang et al., 2000b). 
 
Cutaneous lymphocyte-associated antigen (CLA), is not a chemokine receptor, but is an 
important skin-homing molecule for T cells (Picker et al., 1990a). CLA is expressed on 
10-15 % of circulating T cells and on 80-90% of T cells in the inflamed skin (Picker et al., 
1990b), and the expression of CLA is induced in naive T cells after they have been 
converted to memory T cells in skin draining LNs (Picker et al., 1993). The CLA structure 
is similar to the carbohydrate structure sialyl Lewis X antigen (sLe(x)) (Fuhlbrigge et al., 
1997). These carbohydrate structures are ligands for L-, P- and E-selectins, adhesion 
molecules that are expressed by leukocytes (L-selectin), platelets (P-selectin) or 
endothelial venules after stimulation with inflammatory agents (E- and P-selectin) 
(Bevilacqua et al., 1987; Gallatin et al., 1983; Hattori et al., 1989; Springer, 1994). CLA 
binds to E-selectin on the endothelium and treatment with anti-CLA antibody, HECA-452, 
can block this interaction (Berg et al., 1991). Binding initiates the tethering and rolling of 
T cells on the vascular endothelium, an event which eventually leads to extravasation of 
these cells into the skin. CLA+ T cells are of special importance in the pathomechanisms 
of AD and ACD since CLA+ T cells have been shown to be activated by antigens relevant 
to both of these diseases, such as house dust mite or nickel (Santamaria Babi et al., 1995).  
5.2 Allergy 
When an immune response is mounted against a harmless antigen or in an exaggerated 
form, the term hypersensitivity is used. Coombs and Gell divided hypersensitivity 
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reactions into four different subtypes (Gell and Coombs, 1963). The type I 
hypersensitivity reaction is an immediate response to a soluble antigen and is mediated by 
antigen-specific IgE on the surface of mast cells and basophils. Type II hypersensitivity is 
mediated by IgG antibodies which are directed against cell- or matrix associated antigens 
and results in tissue injury. Type III hypersensitivity reactions are also mediated by IgG 
antibodies, but are directed to soluble antigens, leading to formation of immune 
complexes that persist and deposit in the blood vessels, tissues or organs where they 
induce activation of leukocytes and complement and subsequently tissue damage. Type IV 
hypersensitivity, also called delayed type hypersensitivity, is mediated by allergen-specific 
T cells and usually occurs several hours or days after antigen exposure. Allergy is the most 
common type of hypersensitivity and although often equated with type I hypersensitivity 
reactions, it can have features of all these four types of reactions (Gell and Coombs, 1963; 
Rajan, 2003). In the context of AD and ACD, the inflammatory response is mediated 
mainly by type I and type IV hypersensitivity responses and they will be discussed in 
more detail later. 
 
An allergic reaction occurs in response to certain innocuous antigen, called allergen. 
Allergen is most often a highly soluble protein or a glycoprotein of relatively small size 
and the exposure occurs usually at very low doses. An individual can also become 
sensitized to chemicals, which are not immunogenic by themselves but which can trigger 
immune responses after binding to protein carriers. Usually the first encounter with an 
allergen does not lead to an allergic reaction but to the formation of allergen specific 
antibodies or memory T cells (Kimber et al., 2011; Platts-Mills and Woodfolk, 2011).  
 
Genetics are important factors in determining an individual's susceptibility to develop 
allergy. However, the rapid increase in the incidence of allergies cannot be explained by 
genetic factors alone and it has been estimated that environment and genetic variation each 
account for about 50 % of the risk of allergic diseases. Changes in hygiene, pollution, 
allergen levels and diets have been postulated to be responsible for the increased 
prevalence rates of allergy (Horner, 2006; Murphy et al., 2008; Rautava et al., 2005; 
Saxon and Diaz-Sanchez, 2005). One of the most widely accepted theories, however, is 
the hygiene hypothesis, which indicates that allergic diseases have become increased in 
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industrialized countries due to the reduced microbial burden (Wills-Karp et al., 2001) and 
may result in the lack of induction of regulatory T -cell populations during infection 
(Maizels, 2005). Treg cells are known to control Th2 responses (Lin et al., 2005) and e.g. 
Treg cells activated during helminth infection protect against subsequent airway 
inflammation (Wilson et al., 2005). 
5.2.1 Type I hypersensitivity 
A type I hypersensitivity reaction can be divided into immediate reactions occurring 
within seconds after antigen encounter, and late-phase responses emerging 8-12 hours 
later. In the immediate reaction, allergen induced cross-linking of FcεRI receptors on mast 
cells induces a process called degranulation, where preformed inflammatory mediators 
stored inside cytoplasmic granules of mast cells and also newly formed mediators are 
released. These mediators include histamine, tryptase, cytokines, chemokines and lipid 
mediators such as prostaglandins and leukotrienes. The release of these agents induces 
smooth muscle contraction, increased vascular permeability and secretion of mucus. In 
addition, it results in the recruitment of other inflammatory cells, such as eosinophils, 
basophils, T cells and DCs to site of antigen encounter and initiation of late-phase 
responses in half of the patients (Fig. 2). These events also underlie the development of T 
cell and eosinophil mediated allergic tissue inflammation which may develop into chronic 
allergic diseases like AD or asthma. Type I hypersensitivity reaction is usually a very local 
event, occurring at a small area around allergen encounter and mast cell activation. 
However, in some cases disseminated mast cell activation can occur, resulting in a life-
threatening systemic response, anaphylactic shock (Burton and Oettgen, 2011; Finkelman 
et al., 2005; Rajan, 2003). 
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Figure 2  Type I hypersensitivity reaction. (A) In the resting state, allergen specific IgE 
 molecules are bound to FcεRI on mast cells. (B) When an allergen enters the body, it 
 crosslinks FcεRI by binding to IgE molecules and leads to degranulation of mast 
 cells. In degranulation, preformed mediators are released and induce the hallmarks 
 of immediate type reaction such as itching, swelling, mucus production or 
 bronchoconstriction. In addition, in some patients inflammatory mediators released 
 by mast cells recruit other cells of the immune system to the site of allergen 
 encounter, resulting in the late-phase response characterized by infiltration and 
 activation of eosinophils, basophils and T cells.(Burton and Oettgen, 2011; Murphy 
 et al., 2008) 
5.2.2 Type IV hypersensitivity 
The evidence that type IV hypersensitivity is especially mediated by antigen-specific T 
cells, rather than antibodies, emerges from animal experiments where sensitivity to a 
certain antigen can be transferred from one sensitized animal to a non-sensitized 
counterpart through adoptive transfer of antigen-specific T cells but not by transfer of 
serum. The type IV hypersensitivity can be divided into the sensitization phase and the 
elicitation phase. In the sensitization phase, the allergen is taken up by APCs and 
presented to naive T cells in the draining LNs, where the activation of T cells eventually 
leads to the formation of antigen-specific memory T cells. These memory T cells then 
remain in the LNs, enter the bloodstream or migrate to the tissue. No clinical symptoms 
are usually observed at this point. Upon subsequent exposure to the same allergen, 
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memory T cells residing in the tissue or recruited from the blood and LNs are activated 
directly at the site of allergen exposure. In most cases, the activated T cells are CD8+ Tc1 
and CD4+ Th1 cells which, upon antigen recognition, trigger apoptosis of the tissue cells 
and release inflammatory cytokines such as IFN-γ and IL-17, which in turn activate the 
residential tissue cells. They further amplify the inflammatory response by releasing a set 
of cytokines and chemokines, including CXCL9, CXCL10, IL-1 and GM-CSF, that 
enhance vascular permeability and expression of adhesion molecules on endothelium, 
recruit monocytes and more T cells to the site of allergen encounter and contribute to 
monocyte maturation into macrophages. Since a fully mounted type IV hypersensitivity 
reaction takes 24-48 hours to develop, this type of response is also called delayed-type 
hypersensitivity reaction (Kalish and Askenase, 1999; Murphy et al., 2008; Roitt et al., 
1996; Vocanson et al., 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Type IV hypersensitivity reaction (A) During the sensitization phase, the allergen is 
 taken up and processed by dendritic cells. (B) Upon processing, dendritic cells 
 mature and migrate to draining lymph nodes where they present the antigen to naive 
 T cells (Tn). (C) Naive T cells become activated and generate memory T cells (Tm). 
 (D) Upon re-encounter with the same allergen, memory T cells are activated to 
 become effector T cells (Te) at the site of allergen exposure. Effector T cells induce 
 tissue damage and produce inflammatory cytokines that activate residential cells to 
 produce inflammatory mediators. These mediators then recruit other inflammatory 
 cells to the site of allergen encounter to further amplify the inflammatory response 
 (Kalish and Askenase, 1999; Vocanson et al., 2009).  
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5.3 Atopic dermatitis 
Atopic dermatitis is a chronic inflammatory skin disorder, characterized by itching, 
relapsing dermatitis and skin lichenification. The lesional skin is occupied by increased 
numbers of T cells, eosinophils and mast cells. Previously atopic dermatitis was divided to 
non-IgE associated (intrinsic) and IgE associated (extrinsic) form but the World Allergy 
Organization (WAO) has defined the term "atopy" to be used only in association with IgE 
sensitization (Johansson et al., 2004). However, non-IgE associated AD can be a transient 
phase in the development into IgE associated AD, especially in children (Bieber, 2010; 
Novembre et al., 2001). It also has to be noted that much of the research has been 
conducted on AD before WAO definition and therefore the AD-related findings described 
below do not necessarily always discriminate between IgE and non-IgE associated forms 
of AD. 
 
The inflammatory response can be triggered by many factors such as food, airway 
allergens, irritative substances and microorganisms (Werfel, 2009). The acute phase of the 
inflammatory response in the skin is dominated by Th2 cells but the chronic phase is 
maintained by Th1 promoting cytokines, IL-12 and IL-18, in addition to remodelling 
associated cytokines IL-11, IL-17 and TGF-β (Grewe et al., 1998; Toda et al., 2003).  
 
For unknown reasons, the prevalence of AD has been on the increase during the last 
decades, and the life-time prevalence in school-aged children in some western societies 
has been reported to be as high as 17 %. In almost half of the cases, AD develops during 
the first 6 months of life and in 85 % of the cases, the onset of AD occurs before the age of 
five (Bieber, 2010). In addition, over 60% of AD patients develop other allergies or 
asthma later in life (Boguniewicz and Leung, 2010; Spergel, 2010). 
5.3.1 Genetics 
Genetic factors play an important role in the onset of AD, as demonstrated in twin studies 
and family-based linkage studies that have reported a twofold incidence rate for AD when 
one of the parents is affected and threefold incidence rate when both parents have AD 
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(Dold et al., 1992; Schultz Larsen and Holm, 1985). Polymorphism in the genes 
controlling either skin barrier function or adaptive and innate immune responses has been 
observed in several genome-wide linkage studies in AD patients (Barnes, 2010). 
 
A chromosomal region including epidermal differentiation complex harbours over 50 
genes controlling epidermal homeostasis (Bieber, 2010). At the moment, one of the most 
extensively studied genes in this region is filaggrin-gene (FLG), and mutations within this 
gene has been shown to associate with AD in at least 20 different studies (Barnes, 2010). 
Loss-of-function mutation in the profilaggrin/filaggrin gene creates defects in the skin 
barrier function (Palmer et al., 2006) and not only facilitates the allergen penetration into 
the skin but might also render these patients more susceptible to suffer disseminated viral 
infections, which has consequences for the disease severity (Barnes, 2010; Spergel, 2010). 
Several studies have shown that approximately 30 % of the AD patients have at least one 
mutation in the filaggrin-gene (Marenholz et al., 2006; Palmer et al., 2006; Weidinger et 
al., 2006) and compared to AD patients without FLG mutation, these patients have an 
earlier onset, more severe and persistent form of AD (Henderson et al., 2008) and are 
more likely to develop asthma or other allergies later on (Marenholz et al., 2006; Palmer 
et al., 2006). However, not all the AD patients have filaggrin mutations, indicating that 
also other factors contribute to the defective skin barrier observed in the majority of AD 
patients. As mentioned above, several other skin barrier-related genes have still to be 
investigated and may prove to be important in the pathogenesis of AD. In addition, 
production of Th2 cytokines reduces filaggrin expression in keratinocytes (Howell et al., 
2007) and downregulates the expression of two other important proteins involved in 
epidermal differentiation, loricrin and involucrin (Kim et al., 2008), possibly inducing an 
impaired skin barrier function in patients with an inherited preference for Th2 polarization 
(Brown and McLean, 2009). It is also of interest that 40 % of people with null mutations 
in the filaggrin gene do not develop AD (Henderson et al., 2008), suggesting that 
polymorphism in other genes and/or the contribution of environmental factors are required 
for AD to develop (Barnes, 2010).  
 
In addition to genes controlling skin barrier functions, genes involved in immunological 
mechanisms are involved in the development of AD. Polymorphisms in the genes 
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encoding IL-4 (He et al., 2003; Kawashima et al., 1998), IL-4 receptor (Hosomi et al., 
2004; Oiso et al., 2000) or IL-13 (He et al., 2003; Liu et al., 2000; Tsunemi et al., 2002) 
have been observed in AD patients. In addition, defects in PRRs of the innate immune 
system, such as toll like receptors (TLR), may change the function of these receptors so 
that they are no longer protective against allergy. For example, polymorphisms in genes 
encoding TLR2 and TLR9 have been shown to associate with AD (Ahmad-Nejad et al., 
2004; Novak et al., 2007). Keratinocytes secrete TSLP, which instructs DCs to induce Th2 
responses. Elevated TSLP expression has been detected in the lesional AD skin (Ito et al., 
2005). In addition, polymorphism in the gene encoding mast cell chymase, an enzyme 
which increases vascular permeability and accumulation of inflammatory cells, correlates 
with the incidences of AD (Mao et al., 1996; Weidinger et al., 2005). 
 
Some of the AD patients display defects in anti-microbial peptide (AMP) expression 
which might be one explanation for the increased susceptibility for infections (Nomura et 
al., 2003; Ong et al., 2002) and subsequent exacerbated skin inflammation in AD patients. 
Decreased AMP production may be a secondary effect of Th2 dominated milieu in AD, 
since Th2 cytokines have been shown to downregulate the AMP expression from 
epidermal cells in vitro (Howell et al., 2006). Local and disseminated viral infections can 
even induce potentially life-threatening complications in AD patients (Peng et al., 2007; 
Vora et al., 2008). Enhanced susceptibility for viral infection can be partly due to an 
altered phenotype or lowered numbers of plasmacytoid DCs in AD lesions or decreased 
production of anti-viral cytokines by pDCs and mDCs (Lebre et al., 2008; Novak et al., 
2004a; Wollenberg et al., 2002). 
 
In addition to the above mentioned defects, many other factors, such as abnormally high 
expression of FcεRI on Langerhans cells and inflammatory dendritic epidermal cells 
(IDEC), elevated numbers of skin-seeking, CLA+, T cells or increased production of 
neuropeptides and neurotropins, which may enhance eosinophil survival and the 
chemotactic response, have also been shown to have possible effects in the 
pathomechanisms of AD (Bieber, 2010; Boguniewicz and Leung, 2010; Werfel, 2009).  
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5.3.2 Environment 
Although genetics are important risk factors for AD, the rapid increase of this disease 
indicates that environmental factors also play a crucial role. For example, rural versus 
urban living environment (von Mutius, 2002), diet (Rautava et al., 2005), exposure to 
pollutants (Saxon and Diaz-Sanchez, 2005) or infectious and non-infectious microbes 
(Horner, 2006) all have an effect on allergy risk. However, the ISAAC study demonstrated 
that within the same regions, changes in prevalence were different for asthma, allergic 
rhinitis and atopic eczema, suggesting that different allergic diseases might have different 
environmental risk factors (Asher et al., 2006).  
 
Foodborne allergens are important triggers of cutaneous responses, especially in children 
with AD. Often sensitization to food allergen occurs prior to ingestion, suggesting that an 
impaired skin barrier function might play a role. In addition, allergens in breast milk and 
enhanced antigen transfer through the gut barrier in AD patients are factors that probably 
contribute to the sensitization process (Hauk, 2008). 
 
Impaired skin barrier most likely plays a role also in the sensitization to airborne allergens, 
of which house dust mites, cockroach, pet dander, and different kind of pollens are most 
relevant for AD. They can contribute to the atopic inflammation either through their 
intrinsic proteolytic activity, activation of proteinase-activated receptor-2 (PAR-2), or IgE 
binding. The innate proteolytic activity can destroy epithelial tight junctions directly, 
participate in the degranulation of eosinophils and activate keratinocytes. These effects 
contribute to increased local inflammation, barrier impairment and delayed barrier 
recovery. The barrier impairment is also observed when airborne proteins bind to PAR-2 
and induce changes in keratinocyte calcium levels. In addition, PAR-2 activation is 
associated with chronic itch, leading to scratching and further impairment of the barrier. 
The binding of airborne allergens to IgE triggers the classical immediate type response 
(Hostetler et al., 2010).  
 
Finally, the toxins produced by skin colonizing bacteria, as well as viral infections, can 
trigger the inflammation in AD-patients (Werfel and Kapp, 1998).  
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 5.3.2.1 Superantigens 
Superantigens (SAg) are proteins produced by bacteria or viruses that activate T cells by 
binding to the MHC molecules outside their peptide-binding grooves and to T cell 
receptors outside their antigen recognition sites. This interaction is antigen non-specific 
and leads to massive proliferation of T cells. SAgs are able to stimulate simultaneously 5-
20% of the T cell population compared with 1 in 105-106 T cells during normal antigen 
presentation (Sundberg et al., 2002). The same bacteria can produce a variety different 
SAgs, e.g. the sequencing of the whole genome of Staphylococcus aureus has revealed at 
least 70 new virulence factors, many of which are most likely also to exert superantigenic 
properties (Kuroda et al., 2001). However, it is not known at the moment how invading 
pathogens benefit from overactivation of T cell responses.  
 
Superantigens have been shown to exacerbate skin inflammation in AD-patients through 
several mechanisms. First, they induce production of SAg-specific IgE (Laouini et al., 
2003; Leung et al., 1993). Second, they induce secretion of inflammatory cytokines, such 
as TNF-α, IL-17 and IL-22 (Miethke et al., 1992; Nograles et al., 2009; Wang et al., 
2009a). Third, they can activate large numbers of T cells in an antigen non-specifical 
manner (Hong et al., 1996; Kappler et al., 1994). Finally, superantigens inhibit the 
suppressive function of Treg cells (Cardona et al., 2006; Lin et al., 2011). 
 
5.3.3 Stress  
Stress can sometimes provoke or exacerbate eczema, and the connection between the skin, 
the immune system and the nervous system has attracted increasing interest in recent 
years. The innervation of the skin is very dense, and at least keratinocytes, skin dendritic 
cells and mast cells have been shown to have connections with nerve fibers and axons. In 
addition, certain neurotransmitters can be produced not only by nerve fibers but also 
keratinocytes, melanocytes and all cells of the immune system, and most cutaneous cells 
also express receptors for these neuromediators. Neuromediators can modulate the 
function of cutaneous cells and immune cells, such as Langerhans cells. During times of 
stress, release of neurotransmitters and nerve growth factors in the blood or skin is 
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increased and this can enhance the inflammation induced by immune cells. In AD lesions, 
various changes in skin neurobiology are observed, strongly suggesting that the nervous 
system plays a significant role in the pathomechanisms of AD (Misery, 2010). 
 
In summary, it is unlikely that a few dominant risk factors would explain the increase in 
AD rates, but instead, certain risk factors can be of different importance in distinct 
populations, depending on the environment and the genetic background of the particular 
population. It is also possible that AD is a group of several diseases sharing a common 
phenotype, and having various, possibly even opposing, risk factors (Williams et al., 
2008).  
5.4 Allergic asthma 
Atopic dermatitis in early childhood is often the first step in the so-called atopic march 
being followed by asthma or allergic rhinitis in majority of the patients (Spergel, 2010). 
Therefore, a link between skin sensitization and a subsequent asthma development has 
been studied in several experiments which demonstrate that epicutaneous or 
intracutaneous protein exposure induces airway hyperresponsiveness in mice when the 
same antigen is administered into the lungs (He et al., 2007; Lehto et al., 2005; Spergel et 
al., 1998).  
 
Asthma has been defined as "a chronic inflammatory disorder of the airways in which 
many cells and cellular elements play a role. The chronic inflammation is associated with 
airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, 
chest tightness, and coughing, particularly at night or in the early morning. These episodes 
are usually associated with widespread, but variable, airflow obstruction within the lung 
that is often reversible either spontaneously or with treatment" (GINA, 2011). Today, it 
has become more and more evident that asthma is rather several diseases occurring as a 
consequence of many different pathomechanisms, having various levels of severity and 
types of treatment responsiveness, with virtually the only common feature being airflow 
obstruction of variable magnitude (Lötvall et al., 2011). Several attempts have been made 
to define different types of asthma, and they are referred to as endotypes or phenotypes of 
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asthma. These definitions range from simple division into allergic and non-allergic asthma 
to more precise types, e.g. different endotypes/phenotypes are defined based on the 
triggers of the asthma response, clinical phenotype, type of inflammation etc. (Anderson, 
2008; Handoyo and Rosenwasser, 2009; Lötvall et al., 2011; Wenzel, 2006). 
 
This thesis will concentrate only on allergic asthma which in its simplest form refers to a 
response where airway exposure to an allergen triggers an immediate, type I, 
hypersensitivity response in a sensitized individual. Allergen-induced crosslinking of IgE 
molecules on mast cells triggers the release of preformed mediators, which induce 
bronchoconstriction, evoke mucus production and vascular leakage and initiate the 
recruitment of T cells. This early-phase asthmatic response is followed by a late-phase 
response several hours laters, which involves the influx and activation of eosinophils and 
T cells in the airways (Afshar et al., 2008). T cells of Th2 type are of special importance 
in allergic asthma, through the induction of eosinophilia and airway hyperresponsiveness 
(Brusselle et al., 1995; Foster et al., 1996; Wills-Karp et al., 1998), but also other T cell 
subsets, such as Th1 (Cembrzynska-Nowak et al., 1993; Medoff et al., 2002), Th17 
(Barczyk et al., 2003; Molet et al., 2001) and γδ T cells (Zuany-Amorim et al., 1998) may 
play a role. In addition, Treg cells are essential in controlling the airway inflammation and 
eosinophilia (Curotto de Lafaille et al., 2008; Kearley et al., 2005; Lewkowich et al., 
2005).  
5.5 Allergic contact dermatitis 
Allergic contact dermatitis is a type IV hypersensitivity reaction which develops in 
response to a hapten in sensitized individuals. A hapten is a low molecular weight 
molecule, such as a chemical or divalent cation, e.g. nickel. It is unable to provoke an 
immune response by itself, but once bound to self proteins, it generates antigenic 
determinants. Much of the knowledge of pathomechanism of ACD results from animal 
studies where the response is termed contact hypersensitivity (CHS). Thus, ACD and CHS 
are synonyms and define a hapten-specific T cell mediated skin inflammation. A fully 
developed ACD response requires two phases, sensitization and elicitation. Finally, a 
resolution phase occurs (Vocanson et al., 2009). 
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The general view is that the CHS response is mediated by CD8+ T cells while CD4+ cells 
mainly participate in the regulation and resolution of the inflammation (Akiba et al., 2002; 
Bour et al., 1995). However, with some haptens, such as fluorescein isothiocyanate 
(FITC), trimellitic anhydride (TMA) and oxazolone (OXA), CD4+ cells have also been 
shown to have effector T cell functions (Dearman and Kimber, 2000; Dearman et al., 
1996; Wang et al., 2000a). In addition, there is one report where the CHS response was 
mounted in RAG2-/- mice which are totally devoid of T- cells. In that experiment, the NK 
cells were identified as the effector cells (O'Leary et al., 2006).  
 
The sensitization phase occurs upon first contact with the hapten and results in the 
generation of antigen-specific memory T cells. Usually at this point, no clinical symptoms 
are observed. When the hapten first arrives at the skin, it forms complexes with epidermal 
proteins and evokes toxic/danger signals that induce innate immune responses in skin 
cells. The inflammatory mediators such as IL-1β and TNF-α released at this point initiate 
recruitment of leukocytes from the circulation, including monocytes, which develop into 
DCs. Inflammatory mediators activate these recruited DCs, Langerhans' cells and dermal 
dendritic cells to take up the hapten-protein complexes, process them and migrate to the 
draining LNs, where the hapten:peptide complex is presented to naive T cells, which then 
differentiate into memory T cells. Additional inflammatory events also can occur at distant 
sites from antigen encounter, e.g. NKT cells in the liver start to produce IL-4 and induce 
recruitment of B cells into the spleen which then start to produce hapten-specific IgM 
antibodies (Vocanson et al., 2009).  
 
If a sensitized individual is re-exposed to the sensitizing hapten, a CHS response occurs. 
This phase is called the elicitation or challenge phase. As in the sensitization phase, hapten 
again forms complexes with epidermal proteins and induces innate immune response 
similarly as in the sensitization phase. In addition, IgM molecules bind the hapten and 
activate complement which in turn stimulates mast cells and induces the production of 
inflammatory mediators such as IL-1β, IL-18 or histamine. This local inflammatory 
response and the release of IL-1β and TNF-α then efficiently recruits CD8+ T cells from 
the circulation into the skin. CD8+ cells become activated by MHC I expressing skin cells, 
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either epidermal DCs or keratinocytes or other residential skin cells, that have taken up the 
hapten and present it to CD8+ T cells (Vocanson et al., 2009). CD8+ cells start to secrete 
IFN-γ, IL-17 and TNF-α (He et al., 2007; Nakae et al., 2002; Wakabayashi et al., 2005) 
and induce keratinocyte apoptosis through the Fas/Fas-L or perforin pathways (Akiba et 
al., 2002; Kehren et al., 1999). At this point, residential skin cells release a new set of 
inflammatory mediators, such as chemokines CXCL9 and CXCL10, which recruit a 
second wave of leukocytes, especially neutrophils, monocytes and more T cells, including 
regulatory T cells. Eczematous lesions appear 24-48 hours post exposure (Vocanson et al., 
2009).  
 
In order to avoid excess damage to the tissue, the inflammatory response in CHS is 
carefully controlled. This suppression involves several different mechanisms such as 
elimination of antigen-loaded DCs, upregulation of regulatory ligands on tissue cells, 
downregulation of adhesion molecules E- and P-selectins on endothelial cells or activation 
of regulatory lymphocytes or mast cells (Grimbaldeston et al., 2007; Loser et al., 2006; 
Melrose et al., 1998; Ring et al., 2009; Yang et al., 2006). In addition, the inflammatory 
response is actively down-regulated by CD4+ T (Treg) cells during the resolution phase 
(Bour et al., 1995; Xu et al., 1996).  
 
Hapten induced skin irritation is essential for the development of the CHS response as 
demonstrated by Grabbe et al. who showed that co-application of a contact sensitizer 
2,4,6-trinitrochlorobenzene (TNCB) together with suboptimal doses of oxazolone was 
sufficient to elicit CHS in oxazolone sensitized mice (Grabbe et al., 1996). This finding 
was confirmed by Bonneville et al. who further demonstrated that the irritant effect is 
crucial for both the development and determining the severity of CHS responses 
(Bonneville et al., 2007).  
5.6 Animal models 
With the help of animal models, complex interactions occurring in the body during an 
allergic response can be studied in a way that would be impossible to examine with cell 
cultures or skin biopsy specimens. Although none of the experimental models can 
 
 
 
 
45
completely mimic human disease, they always share many common features with them. 
Therefore animal models are of great importance in understanding the mechanisms of 
allergic diseases and consequently in designing therapeutic tools to combat these illnesses. 
 
5.6.1 AD-models 
Several models have been used for generating an AD-like skin inflammation in different 
species of experimental animals. However, mice are the most widely used, due to their 
low cost, fast reproducibility and minor variability in results since work can be done with 
inbred strains. In addition, with the help of modern gene-technology, different kinds of 
knock-out and knock-in strains can be generated, offering a vast array of possibilities to 
study the importance of different genetical factors in the pathomechanisms of AD. 
 
A few mouse strains have been described in the literature, which develop a spontaneous 
AD-like inflammation. These are Nc/Nga mice, (Matsuda et al., 1997), which have a 
mutation linked to an increase in IgE levels and Th2 responses (Matsumoto et al., 1999), 
DS-Nh mice which are susceptible for S. aureus colonization (Haraguchi et al., 1997), 
NC/F mice that develop AD-like skin inflammation and have positive patch tests to mites 
(Sugiura et al., 2004), NOA mice, that have increased mast cell numbers in the skin and 
elevated IgE levels, but lack the classical histological features of AD (Watanabe et al., 
1999) and the recently described mouse strain that carries a mutation in the Traf3ip2 
(Act1/CIKS) gene and exhibits elevated IgE levels (Matsushima et al., 2010). In addition, 
a mouse strain with the flaky tail (ft) mutation in chromosome 3, within the mouse 
epidermal differentiation complex, has reduced profilaggrin mRNA expression and 
abnormal levels of profilaggrin which is not processed to filaggrin monomers. These mice 
have a dry and flaky skin and develop eczematous lesions by the age of 32 weeks. In 
addition, they have significantly elevated serum IgE levels (Fallon et al., 2009; Lane, 
1972; Oyoshi et al., 2009). Due to the strong connection between AD and filaggrin 
polymorphism in humans (Palmer et al., 2006), these mice are considered as a useful 
model for studying effects of filaggrin deficiency in AD. 
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However, as mentioned earlier, AD is not induced by a single defect in a single gene but 
different genetical factors together with environment play a role in the development of the 
disease. Therefore a more generalized model is also of great importance when studying 
AD-like skin inflammation. One of the most widely used techniques is epicutaneous 
sensitization to protein allergen, ovalbumin (OVA), through tape-stripped skin (Spergel et 
al., 1998). The purpose of tape stripping is to disrupt the mechanical barrier and also 
mimic scratching occurring in AD patients due to itching. In this model, thickening of the 
epidermis and dermis is observed, CD4+ T cells and eosinophils infiltrate the skin and the 
expression of Th2 cytokines, IL-4, IL-5 and IL-13 is upregulated. In addition, elevated 
total and allergen specific IgE and IgG1 levels in the serum are detected. Epicutaneous 
protein allergen sensitization model has also been performed with house dust mite (HDM) 
allergen, Der p8 (Huang et al., 2003), resulting in similar clinical picture as sensitization 
with OVA. This model of sensitization is of special importance in a sense that clinical 
studies have detected an association between HDM exposure and AD (Kimura et al., 
1998). An AD-like allergic skin inflammation can be also induced by epicutaneous 
superantigen exposure (Laouini et al., 2003). 
 
Oxazolone and TNCB are common haptens used in contact hypersensitivity research and 
are known to provoke Th1 type responses (Bellinghausen et al., 1999; Dearman and 
Kimber, 1992). However, multiple challenges with these contact sensitizers skew the 
inflammatory response towards a Th2 type and induce an AD-like inflammation with 
increased numbers of Th2 lymphocytes, mast cells and eosinophils in the skin as well as 
elevated IgE levels in the serum (Man et al., 2008; Matsumoto et al., 2004). 
 
Finally, several genetically modified transgenic strains such as mice overexpressing IL-4, 
IL-31, TSLP, caspase-1, IL-18, stratum corneum chymotryptic enzyme (SCCE) or 
apolipoprotein C1 (APOC1) and mice deficient in RelB or cathepsin E have been shown 
to develop inflammatory responses with features of AD (Jin et al., 2009). In addition, 
there is one report about the development of AD-like skin lesions in mice after repeated 
intragastric exposure to common food allergens, cow's milk and peanut, together with 
cholera toxin adjuvant (Li et al., 2001). 
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5.6.2 Allergic asthma models 
Most of the asthma research is performed with mouse and the basic protocol of allergic 
asthma involves protein sensitization followed by airway challenge. Sensitization is 
usually done with ovalbumin, although house dust mite extracts and aspergillus have also 
been employed. In a typical experiment, mice are sensitized twice by intraperitoneal 
injections of protein in conjunction with an adjuvant. A resting period of one to two weeks 
is employed between two sensitizations. Approximately one week after last sensitization, 
mice are challenged with aerosolized allergen for three consecutive days and the 
inflammatory parameters are measured two days after last airway challenge (Bates et al., 
2009). Variations of this basic protocol occur; for example sensitization can be achieved 
also through epicutaneous, intracutaneous or intratracheal sensitization routes (He et al., 
2007; Lehto et al., 2005; Lewkowich et al., 2005; Spergel et al., 1998). In addition, the 
allergen can be administered in the challenge phase by inhalation, or the intranasal or 
intratracheal routes (Kaufman et al., 2011; Leech et al., 2007; Lehto et al., 2005). 
5.6.3 CHS models 
In the early days of contact hypersensitivity research, animal experiments were performed 
on guinea pigs (Landsteiner and Jacobs, 1936) and even nowadays, the skin sensitizing 
potentials of different chemicals are studied using guinea pigs. However, due to problems 
with interpretation of some of the results, testing is switching from guinea pigs to the 
mouse. For chemical risk assessment, mouse ear swelling test (MEST) and local lymph 
node assay (LLNA) are used (Basketter et al., 2008; Dearman and Kimber, 1999). In 
MEST, the skin sensitizing potential of a chemical is evaluated by its ability to induce ear 
swelling in previously exposed animals (Gad et al., 1986), whereas in the LLNA, the 
ability of a chemical to induce proliferative responses in the draining LN cells is measured 
(Kimber et al., 1994). When studying the mechanisms of CHS responses, strong 
sensitizers such as dinitrofluorobenzene (DNFB), dinitrochlorobenzene (DNCB), TNCB 
or oxazolone are commonly used (Vocanson et al., 2009). The basic protocol involves 
epicutaneous sensitization on the shaved back or abdomen followed by an epicutaneous 
challenge on the ear after a few days resting period. Ear swelling, cytokine production 
from the ear tissue and cellular responses in the dLN are most often analyzed. 
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6. Aims of the study 
Although the incidence rates for allergic diseases have been high for decades, the 
immunological mechanisms behind allergy have still not been completely clarified. The 
aim of this thesis is to unravel some of the pathomechanisms of allergic skin diseases and 
in this way to contribute to future attempts to manage allergic diseases. 
 
The specific aims were: 
 
1. To study how staphylococcal enterotoxin B modulates atopic dermatitis-like skin 
inflammation. 
 
2. To clarify the role of Treg cells in atopic dermatitis. 
 
3. To assess the importance of Treg cell function during sensitization, elicitation and 
resolution phase of contact hypersensitivity.  
 
4. To explore the effects of CCR4 deficiency in oxazolone induced contact 
hypersensitivity response. 
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7. Materials and methods 
7.1 Animal models 
7.1.1 Mouse strains 
In studies investigating the role of superantigen exposure during allergic skin 
inflammation (I), 6 week old Balb/c mice from Taconic M&B (Ry, Denmark) were used. 
The role of Treg cells in the AD and AD-Asthma model (II) was studied using DEREG 
(Depletion of Regulatory T cells) mice (a kind gift from Professor Tim Sparwasser, 
Hannover, Germany). DEREG mice were originally in the C57/Black background and 
were backcrossed to Balb/c mice from Scanbur (Sollentuna, Sweden) at least five times 
prior to the AD and AD-asthma studies. DEREG mice harbour enhanced green fluorescent 
protein (EGFP) and diphtheria toxin (DT) receptor under the control of Foxp3+ promoter, 
and Foxp3+ cells can be transiently deleted in these mice with DT-treatment. Mice were 
genotyped for the transgene and grouped into DEREG-mice and wild type (WT) mice. 
Due to the need for diphtheria toxin treatment, these mice were used at 10-14 weeks of 
age. In addition, C.Cg-Foxp3tm2Tch/J mice that express EGFP under the control of the 
Foxp3 promoter were obtained from The Jackson Laboratory (Bar Harbor, Maine, USA) 
and used at 10-14 weeks of age for Treg cell kinetic studies in AD model and for 
suppression assay (II).  
 
For Treg depletion studies in the CHS model (III) DEREG mice and their WT littermates 
were kept at C57/Black background and used at 10 weeks of age. The effects of CCR4 
deficiency during CHS (IV) were studied with B6;129P-Ccr4tm1Pwr-mice purchased from 
The Jackson Laboratory (Bar Harbor, Maine, USA), bred as heterozygote and genotyped 
for the CCR4 allele. Mice homozygous for the CCR4 knock-out allele were used in all 
studies with their WT littermates being used as controls. 
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7.1.2 AD-model and AD-asthma model 
The mice were sensitized epicutaneously as previously described (Spergel et al., 1998), 
and shown in figure 4. Briefly, while under isoflurane anesthesia, the backs of the mice 
were shaved with an electric razor, and the skin was tape stripped with an adhesive tape 
(Tegaderm, 3M, Health Care, St Paul, MN) for 2-4 times. A sterile patch (1 cm2) 
moisturized with 100 µl of PBS or ovalbumin (1 mg/ml, Sigma) in PBS, was attached to 
the tape stripped area with adhesive tape and left there until a subsequent similar treatment 
three days later. The patch was removed after first sensitization week. After a two-week 
resting period, a second similar kind of sensitization period was performed followed again 
by a two-week resting period after which a third sensitization week was applied. During 
the third sensitization week, the patch was attached for one additional time, 24 hours prior 
to sacrificing the mouse (Fig. 4).  
 
 
 
 
Figure 4  Basic AD-model with SEB. Mice were epicutaneously sensitized by attaching a patch 
moisturized with allergen/superantigen solution on the shaved and tape stripped skin. 
 
In Treg depletion and Treg kinetics study (II), the third sensitization week was omitted 
from the protocol, in order to avoid excess diphtheria toxin (DT) usage (Fig. 5a). As 
shown by Wang et al, an AD-like Th2 dominated response develops already after a two 
week sensitization period (Wang et al., 2007a). In the depletion studies, both WT and 
DEREG mice received DT (Calbiochem, La Jolla, CA) during the second sensitization 
week, simultaneously with patch attachment. The dosage of DT during the first treatment 
1st sensitization week 2nd sensitization week 3rd sensitization week
Day   1                   4                        22           25                     43                     46     49 50
2wk 2wk
Tape stripping and 100 µl of PBS, OVA, SEB or SEB/OVA Collect samples
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was 1 µg/mouse and during the second treatment, 0.5 µg/mouse. In the airway 
inflammation experiment with DEREG and WT mice (II), the mice were sensitized as 
above and DT was intraperitoneally injected during the second epicutaneous sensitization 
week. After the last patch treatment, the patch was left on for four days, and five days after 
patch removal, the mice were administered intranasally (i.n.) 50 µl PBS or OVA in PBS  
(1 mg/ml) on three consecutive days. Mice were sacrificed and samples collected 48 hours 
after the last i.n. treatment (Fig. 5b). 
 
 
1st sensitization week 2nd sensitization week
Tape stripping and 100 µl of PBS or OVA
(1mg/ml)
Day  1                    4                        22           25  26
Collect
samples
2wk
Diphtheria toxin
1st sensitization week 2nd sensitization week
50 µl of PBS or
OVA (1mg/ml) i.n. 
Tape stripping and 100 µl of PBS or OVA
(1mg/ml)
Day    1                    4                        22         25                  34 35 36    38
Collect
samples
2wk
Diphtheria toxin
A
B
 
 
 
Figure 5  Sensitization protocols for DEREG mice in AD-model and AD-related asthma 
 model.(A) Mice were epicutaneously sensitized in a two-week AD model and DT was 
 administered during the second sensitization week. (B) In the AD-Asthma model, the 
 sensitization and DT treatment was carried on as with AD model. The inflammation 
 was elicited in the airways by three intranasal administrations of OVA. 
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7.1.3 CHS-model 
The mice were anesthetized with isoflurane and the hair of the back was shaved and then 
50 µl of vehicle (acetone:olive oil; 4:1) or 10 mg/ml of 4-ethoxymethylene-2-phenyl-2-
oxazolin-5-one (oxazolone) was pipetted onto the shaved area. Five (III) or seven (IV) 
days later, the mice were again anesthetized, the ear thickness was measured and 25 µl of 
oxazolone-solution (3 mg/ml) was pipetted onto the dorsal side of both ears. The mice 
were sacrificed 24 hours later, ear thickness measured and samples collected. In Treg 
depletion studies (III), 1 µg of DT was intraperitoneally injected one day prior to 
sensitization or one day prior to elicitation (Fig.6). In studies of the kinetics of the 
inflammatory response after elicitation, the degree of inflammation was followed for 24, 
48 or 96 hours. In the kinetic experiments with CCR4-/- mice (IV), mice were sensitized 
as depicted. The mice were killed and samples collected 0, 2, 4 or 7 days after 
sensitization and 0, 4, 12 or 24 hours after elicitation. Ear swelling was measured at 0, 2, 
4, 6, 12 and 24 hours after elicitation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Sensitization protocol in DEREG CHS model. DT was administered either (A) one 
 day prior to sensitization or (B) one day prior to elicitation. 
-1   0                                                    4      5       6       7             9            
Topical oxazolone or 
vehicle 
Topical 
oxazolone
Read-out 
DT 
-1   0                                                    4      5       6       7             9            
Topical oxazolone or 
vehicle 
Topical 
oxazolone
Read-out 
DT 
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7.2 RT-PCR 
For real-time PCR analysis, skin or lung samples were homogenized in Trizol™ 
(Invitrogen, CA, USA) or Trisure™ (Bioline, London, UK), RNA extracted according to 
the manufacturer's instructions and used as a template for cDNA synthesis. Real time 
quantitative PCR was performed using commercial or self-designed primers and probes 
with ABI PRISM 7700 Sequence Detector or 7500 Fast Real Time PCR-system (Applied 
Biosystems, CA, USA). Commercial primers and the probe for ribosomal 18S (Applied 
Biosystems, CA, USA) were used to ensure equal amounts of total RNA in each sample. 
The following sequences of self designed primers and probes were used: CCL4 forward 
primer 5'-TGC TCG TGG CTG CCT TCT-3', reverse primer 5'-CAG GAA GTG GGA 
GGG TCA GA-3' and probe 5'-TGC TCC AGG GTT CTC AGC ACC AAT G-3'. CCR4 
forward primer 5'-TCA TGA CTT CCG TGA CGC TTT-3', reverse primer 5'-GTT TTC 
TTC CTC AGA GCC CTG TT-3' and probe 5'-TCG CCT TGT TTC AGT CAG GGT 
GCC-3'. CCR5 forward primer 5'-TTG CAA ACG GTG TTC AAT TTT C-3', reverse 
primer 5'-TCT CCT GTG GAT CGG GTA TAG AC-3' and probe 5'-AGC AAG ACA 
ATC CTG ATC GTG CAA GCT C-3'. CCL11 forward primer 5'-ATG CAC CCT GAA 
AGC CAT AGT C-3', reverse primer 5'-CAG GTG CTT TGT GGC ATC CT-3' and probe 
5'- AGC ACA GAT CTC TTT GCC CAA CCT GGT-3'. Self designed primers for IFN-γ 
and CCL17 were used in one study (I), otherwise commercial primers and probes for IFN-
γ and CCL17 were used. IFN-γ forward primer 5'-AGC GCC AAG CAT TCA ATG A-3', 
reverse primer 5'-CGC TTC CTG AGG CTG GAT T-3' and probe 5'-ATC CGA GTG 
GTC CAC CAG CTG TTG C-3'. CCL17 forward primer 5'-CAG GAA GTT GGT GAG 
CTG GTA TAA G-3', reverse primer 5'-TGG CCT TCT TCA CAT GTT TGT CT-3' and 
probe 5'-TGT CCA GGG CAA GCT CAT CTG TGC-3'. The RU for each sample was 
calculated as follows: Cycle threshold value (CT) of a sample was determined according to 
the manufacturer’s instructions (Applied Biosystems, CA, USA). First, the CT of 18S 
rRNA sample was subtracted from the corresponding target cytokine CT to obtain the CT. 
Next, the average of 18S CTs of each sample was subtracted from the calibrator CT value 
obtained from "no template control" (NTC) to obtain the calibrator CT. The calibrator CT 
was subtracted from the CT of each experimental sample to obtain CT. Finally, the amount 
of target was normalized to an endogenous control, which was relative to the NTC 
calibrator, by equation 2– CT. 
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7.3 ELISA 
The standard sandwich ELISA was used to detect total and antigen-specific antibody 
levels in the serum. All the antibodies used in ELISAs were purchased from BD 
Pharmingen. Purified mouse IgE was used as a standard. Microtiter plates (Nunc, 
Roskilde, Denmark) were coated with rat anti-mouse IgE monoclonal antibody, serum 
dilutions were added and bound IgE detected with biotin-conjugated rat anti-mouse IgE, 
streptavidin-HRP (BD Biosciences, NJ, USA) and peroxidase substrate reagents 
(Kirkegaard & Perry Laboratories, Gaithersburg, MD). Absorbance was read at 405 nm 
with automated ELISA reader (Titertek Multiscan, Eflab, Turku, Finland). 
 
Ovalbumin-specific IgE or IgG2a were measured either by straight (I) or capture (II) 
ELISA. In the straight method, plates were coated with OVA in 0.05 M NaHCO3, pH 9.6 
and blocked with 3% BSA-PBS.  Diluted sera (1:300, 1:600, 1:1200, 1:2400) in 1 % BSA-
PBS were added and bound IgE/IgG2a was detected with biotin-conjugated rat anti-mouse 
IgE/IgG2a monoclonal antibody, streptavidin-HRP (1:4000) and peroxidase substrate. For 
measurements of SEB-specific IgE and IgG2a, plates were coated with 50 µl of SEB (1 
µg/ml) in 0.05 M NaHCO3, pH 9.6. In the capture method, the plate was coated with rat 
anti-mouse IgE/IgG2a monoclonal antibody in 0.05 M NaHCO3, pH 9.6. Diluted sera 
were allowed to bind to BSA-blocked plates overnight and bound IgE/IgG2a was detected 
with biotinylated OVA, Streptavidin-HRP and peroxidase substrate. Biotinylation of 
ovalbumin was conducted by incubating 1mg of ovalbumin with 411 µg NHS-LC-Biotin 
(Pierce) on ice for two hours. Unbound biotin was removed by centrifuging with 
Centricon-tubes (10 kDa cut off, 10 000 MWCO) at 3600 x g for 20 min, and diluting 
twice with PBS and centrifugation at 3600 x g for 40 minutes. The degree of biotinylation 
of OVA was assessed with liquid chromatography, using ACN gradient 0-100 %, for 30 
min. 
7.4 Histology 
Skin or lung tissue was fixed in 10 % formalin and embedded in paraffin. Multiple 4 µm 
thick sections were stained with Hematoxylin-eosin (H & E) for total cell, eosinophil, 
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lymphocyte and neutrophil counts, toluidine blue for mast cell count and periodic acid 
Schiff (PAS) for mucus producing cell count in lung tissues. BALF-samples were stained 
with May-Grünwald-Giemsa. 
In the immunohistochemical stainings, samples obtained from exposed skin were 
immersed in Tissue-Tek oxacalcitriol compound (Sakura Finetek, Alphen aan den Rijn, 
Netherlands) and frozen on dry ice and then 4-µm frozen sections were fixed with cold 
acetone and immunoperoxidase staining was used to detect CD3, CD4, CD8 (BD 
Biosciences, NJ, USA), Foxp3 (eBiosciences, San Diego, CA) or IL-10 (Abcam, 
Cambridge, UK). Biotin conjugated secondary antibody anti-rat IgG (H+L) was purchased 
from Vector Laboratories (Burlingame, CA). Biotin-conjugated monoclonal antibodies 
were used to stain Vβ8 and Vβ6 (BD Biosciences, NJ, USA) T cell receptors. For 
immunofluorescent staining of CCR4, frozen sections were stained with goat polyclonal 
anti-CCR4 (Abcam, Cambridge, UK) and Alexa Fluor®568rabbit anti-goat IgG (H+L) 
secondary antibody (Invitrogen, CA, USA). 
7.5 Chemotaxis assay (IV) 
For chemotaxis assay, lymph nodes cells of sensitized mice were enriched for CD4+ T 
cells using mouse CD4+ Tcell enrichment kit (StemCell Technologies, Vancouver, BC, 
Canada) and Robosep™. After enrichment, the cells were suspended in complete 
RPMI1640 with 1 % BSA. 100 nM of each chemokine, CCL17, CCL22 or CCL27 (R&D 
Systems), was added to the feeder well (Costar Transwell®, Corning, NY, USA) and one 
million cells were added to the insert with 5 µm pore size. Chemotaxis was allowed to 
proceed for 3.5 hours after which the number of migrated cells was counted and the 
chemotactic index was calculated by dividing the number of migrated cells with the 
number of cells that had migrated into the medium alone. 
7.6 Suppression assay (II) 
CD4+ cells were isolated from LN cell suspensions with the Robosep™ CD4+ cell 
positive selection kit (StemCell Technologies, Vancouver, BC, Canada), and sorted into 
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eGFP+ (~Foxp3+) and eGFP- (~Foxp3-) fractions with FACS Aria (BD Biosciences, NJ, 
USA). CD4+ Foxp3- cells from OVA treated mice were used as responder cells, seeded at 
3 x 104 cells per well in complete RPMI-1640 medium (Invitrogen Life Technologies, 
Carlsbad, CA, USA), and stimulated with α-CD3 (0.75 µg/ml) and α-CD28 (2.5 µg/ml) in 
the presence of CD4+ Foxp3+ cells from PBS or OVA treated mice at different ratios 
(responder:Treg cells; 1:0; 1:1 and 1:2). The cells were cultured in 37°C/5% CO2 for 72 h, 
and pulsed with 1 µCi [3H] thymidine per well (Amersham Biosciences Europe, Freiburg, 
Germany) for the last 18 h. Incorporated radioactivity was determined using a liquid 
scintillation counter (Trilux 1450 Microbeta, Wallac, Turku, Finland). The results are 
expressed as mean counts per minute of triplicate wells. 
7.7 Lymph node stimulations 
Cells from draining lymph nodes (axillar in AD and in CHS after sensitization or cervical 
in CHS after elicitation) were isolated by crushing the nodes, which were then filtered 
through a 100 µm strainer and washed with PBS.  
 
(I) Cell suspensions of pooled (4 mice per group) lymph node cells were prepared from 
sensitized mice in complete RPMI 1640 (5 % FBS, 1 mM sodium pyruvate, 50 µM 2-ME, 
100 U/ml penicillin 100 µg/ml streptomycin and 2 mM glutamate) medium (Gibco, 
Invitrogen Corp., UK). The cells were cultured in the medium at 5 x 106 cells/ml in 24-
well plates in the presence of SEB (1 µg/ml) or OVA (50 µg/ml) for six hours. 
Commercial mouse IL-13 (R&D Systems, Germany) and IFN-γ (eBioscience, San Diego) 
immunoassays were used to measure protein from cultured cell supernatants according to 
the manufacturer's instructions.  
 
 (II) LN cell suspensions were stimulated with α-CD3 and cytokine production was 
measured at 48 hours with commercial ELISA kits. OptEIA™Set Mouse IL-5 (BD 
Biosciences, San Jose, CA, USA) was used for detection of IL-5, Mouse IL-4 ELISA 
Ready-SET-Go! (eBioscience, San Diego, CA, USA) for IL-4 and Quantikine® M 
MURINE mouse IL-13 (R & D Systems, Minneapolis, MN, USA) for IL-13. For flow 
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cytometric analysis of intracellular IL-13 and IFN-γ production, cells were stimulated 
either with OVA (50 µg/ml) or with PMA (20 ng/ml) and ionomycin (1 µg/ml) in the 
presence of Brefeldin A (10 µg/ml) for 4 hours.  
 
(IV) In the intracellular cytokine analysis with flow cytometry, cells were stimulated with 
PMA (20 ng/ml) and ionomycin (1µg/ml) in the presence of Brefeldin A (10 µg/ml) for 5 
hours. A sample of stimulated cells were also lysed in Trizol™ (Invitrogen, CA, USA), 
RNA isolated as mentioned above and subjected to cDNA-synthesis and subsequent RT-
PCR analysis.  
7.8 Flow cytometric analysis of skin leukocytes and BALF (II, 
III, IV) 
A piece of inflamed skin was cut into very small pieces, passed through a 70 µm cell 
strainer (BD Biosciences, NJ, USA), centrifuged at 120 x g for 10 minutes, washed with 
PBS and filtered again through a 40 µm cell strainer (BD Biosciences, NJ, USA). BALF 
cells were used as such. Unstimulated cells were surface stained in different combinations 
with the following antibodies: Alexa Fluor™488 conjugated anti-CD3(eBiosciences, CA, 
USA), PE-Cy7™ conjugated anti-CD3 (BD Biosciences), PerCP-Cy5-conjugated anti-
CD4, Alexa Fluor™700-conjugated anti-CD8, APC-conjugated CD103, PerCP-Cy5.5™-
conjugated CD11b, APC-Alexa750™-conjugated CD11c, PE-conjugated CD86 and APC-
conjugated CD80 (eBiosciences). CCR10 was stained using anti-CCR10 (Capralogics, 
MA, USA) and a secondary PE-conjugated anti-goat antibody (R&D systems, 
Minneapolis, USA). In the intracellular Foxp3 or Ki-67 staining, cells were fixed and 
permeabilized with a commercial Foxp3 staining kit (eBiosciences, CA, USA) according 
to the manufacturer’s instructions and stained with PE- or Alexa Fluor™700-conjugated 
Foxp3 or PE-conjugated Ki-67 (BD Biosciences). Intracellular staining of CD69 (II) or 
CTLA-4 (III) was done with APC-conjugated CD69 (eBiosciences) or PE-conjugated 
CTLA-4 (eBiosciences) using Fix and Perm kit from Caltag (CA, USA) according to 
instructions. For analysis of cytokine production, cells were stimulated with PMA (20 
ng/ml) and ionomycin (1µg/ml) in the presence of Brefeldin A (10 µg/ml) for 4-5 hours, 
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after which the cells were washed, surface stained as above, fixed and permeabilized with 
Fix and Perm kit from Caltag and stained with PE-conjugated anti-IL-13 and APC-
conjugated IFN-γ (eBiosciences, CA, USA) The samples were run with FacsCantoII (BD 
Biosciences, NJ, USA) using FACS Diva software and the data was analyzed with FlowJo 
software(Tree Star Inc., Ashland, OR, USA). 
 
7.9 Statistical analysis 
Statistical analyzes were done with Student's t-test or nonparametric Mann-Whitney U test 
using GraphPad Prism™ software. 
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8. Results 
8.1 Effects of topical superantigen exposure in experimental 
AD-model (I) 
Over 90 % of AD patients suffer from Staphylococcus aureus colonization on the skin 
whereas this is much less common in the healthy population i.e. 5-10 % (Aly et al., 1977; 
Leyden et al., 1974; Michie and Davis, 1996). S. aureus is able to produce exotoxins with 
superantigenic properties, such as staphylococcal enterotoxins A-E, G-J and toxic shock 
syndrome toxin-1(Fraser and Proft, 2008). These toxins can exacerbate skin inflammation 
through several mechanisms. The effects of staphylococcal enterotoxin B (SEB) exposure 
on skin inflammation was examined in a murine model of atopic dermatitis. 
 
SEB was introduced onto the skin epicutaneously, in the presence or absence of OVA. 
SEB alone induced thickening of the skin and infiltration of T cells, mast cells and 
eosinophils (I, Fig. 1 and 2a). Simultaneous application of SEB with OVA significantly 
exacerbated the OVA-induced skin inflammation as evidenced by enhanced thickening of 
the dermis and increased numbers of T cells and mast cells in the skin (I, Fig. 1 and 2a). 
Immunohistochemical stainings revealed that compared to OVA exposed mice, 
significantly increased numbers of CD8 cells infiltrated the epidermis in SEB and 
OVA/SEB exposed mice, especially of TCRVβ8+ subtype (I, Fig. 2).  
 
The mRNA analysis of the skin demonstrated that SEB alone was able to induce IL-4 and 
IL-13 expression and moreover, enhanced the OVA induced expression of these 
cytokines. Additionally, SEB elicited the expression of Th1 cytokines, IL-12p40 and IFN-
γ, which were not induced or were induced only modestly after OVA exposure (I, Fig. 3). 
Furthermore, the expression levels of several proinflammatory chemokines (CCL3, CCL4 
and CCL8), Th2 chemokines (CCL1, CCL11 and CCL17) and Th1 chemokines (CXCL9, 
CXCL10 and CXCL11) were elevated in OVA treated mice when the animals were 
simultaneously exposed to SEB (I, Fig. 4). 
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Stimulation of dLN cells with OVA induced a significant IL-13 production in OVA and 
OVA/SEB sensitized mice whereas no IL-13 production was detected in PBS- or SEB 
treated mice. Also SEB stimulation resulted in IL-13 production in SEB and OVA treated 
mice but not in OVA/SEB mice. However, the SEB induced IL-13 levels were much 
lower compared to OVA induced levels (I, Fig 5a). Instead, IFN-γ production was induced 
only after SEB stimulation from cells derived from SEB and OVA/SEB mice but not from 
PBS or OVA sensitized mice (I, Fig. 5b). Finally, SEB exposure significantly enhanced 
total IgE and OVA- specific IgE and IgG2a production. Moreover, SEB induced the 
prodcution of SEB-specific IgE and IgG2a (I, Fig. 6). 
8.2 Role of Foxp3+ Treg cells in experimental AD-model (II) 
In the two-week AD model, the infiltration of eosinophils and T cells into the skin was 
significantly increased after epicutaneous ovalbumin (OVA) exposure (II, Fig. 1b). In 
addition, the expression levels of Th2 cytokines IL-4 and IL-13 and anti-inflammatory 
cytokine IL-10 were upregulated after OVA treatment. Instead, the IFN-γ mRNA 
expression was at a similar level as encountered in the PBS control mice (II, Fig. 1c). In 
addition, total and OVA-specific IgE levels in the serum were significantly increased after 
OVA treatment (II, Fig 1d). According to IHC stainings, the number of Foxp3+ cells in 
the skin was significantly elevated after OVA sensitization (II, Fig 1e), but the ratio of 
Foxp3+ cells/CD3+ cells was unchanged (II, Fig. 1f). In addition, time point experiments 
revealed that the percentages of Foxp3+ cells in the draining LNs were maintained at 
similar levels throughout the protocol (II, Fig. 1g), but the portion of activated memory 
Treg cells (CD103+) gradually increased (II, Fig. 1h). Moreover, OVA treatment resulted 
in the accumulation of both Foxp3- and Foxp3+ IL-10+ expressing T cells in the skin (II, 
Supplementary fig. 1). 
 
LN cells from OVA sensitized mice showed a strong Th2 cytokine production after α-CD3 
stimulation (II, Fig. 2a). As IL-4 has been shown to diminish the suppressive capacity of 
Treg cells (Dardalhon et al., 2008), the suppressive capacity of Treg cells derived from 
PBS or OVA sensitized mice was studied. The Treg cells from OVA sensitized mice were 
significantly impaired in their ability to suppress T cell proliferation (II, Fig. 2b).  
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Next the effect of Foxp3+ cell depletion in AD model was examined in DEREG mice. 
Foxp3+ Treg cells were depleted during the second sensitization week with an 
intraperitoneal injection of DT. Also, the effects of sole DT treatment on naive mice were 
studied. DT injection resulted in greatly reduced Foxp3 expression in the skin and LNs, at 
both the mRNA and protein levels (II, Fig. 3b-d). DT administration into naive DEREG 
mice revealed no inflammatory response in the skin, indicating that Foxp3+ depletion did 
not provoke spontaneous skin inflammation. Instead, the skin injury induced by tape 
stripping increased cellular infiltration and the mRNA expression of IL-4, IL-13 and IFN-
γ in DEREG PBS mice as compared with WT. OVA exposure further enhanced the 
cellular infiltration and the expression of Th2 cytokines and more in DEREG mice than in 
WT (II, Fig. 4a-c and Supplementary fig. 2). Furthermore, a larger percentage of OVA 
stimulated LN cells produced IL-13 in DEREG mice (II, Supplementary fig. 3) and total 
IgE and OVA-specific IgE and IgG2a levels in the serum were significantly elevated in 
comparison with WT mice (II, Fig. 4d). The mRNA expression of anti-inflammatory IL-
10 was also upregulated in DEREG OVA mice, this being confirmed at the protein level 
as well (II, Supplementary fig.1). 
 
To assess the phenotype of the remaining/regenerated subsets of Foxp3+ and Foxp3- 
regulatory T cells after depletion, LN cells were stained for PD-1 and Helios. PD-1 is 
expressed both by nTreg and iTreg cells, but at a higher level by iTreg cells (Haribhai et 
al., 2011), whereas Helios has been described as a marker for nTreg cells (Thornton et al., 
2010). In the DEREG mice, the frequency of PD-1+ Foxp3+ and PD-1+ Foxp3- cells was 
significantly higher, and the percentage of Helios+ Foxp3+ T cells was slightly lower than 
in the WT mice (Supplementary figure 4).  
 
Treg mediated suppression is directed at Teff cells directly or via DCs (Tang and 
Bluestone, 2008). Treg depletion induced changes were investigated in both of these cell 
types. The number of CD4+ and CD8+ T cells as well as CD11c+ dendritic cells (DC) was 
significantly higher in the LNs of OVA treated DEREG mice (II, Fig. 5a). In accordance 
with this finding, a higher percentage of these cells stained positive for the proliferation 
marker, Ki-67 (II, Fig. 5b). A greater percentage of both CD4+ and CD8+ T cells 
expressed the activation marker, CD69, in DEREG mice (II, Fig. 5c). In addition, a larger 
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proportion of DCs expressed costimulatory molecules CD80 and CD86 (II, Fig. 5d) and 
the mRNA expressions of CD80 and CD86 were elevated also in the skin (II Fig. 5e). 
Finally, there was a clear accumulation of CD11bhiCD11c+ inflammatory DCs (Hammad 
et al., 2009) and skin derived EpCam+ DCs (Nagao et al., 2009) in the draining LN of the 
Treg depleted mice (Fig. 5f). 
 
Epicutaneous sensitization can lead to airway inflammation when the sensitizing antigen is 
administered into the lungs (Lehto et al., 2005; Spergel et al., 1998), indicating a 
relationship between skin sensitization and subsequent development of asthma. It was 
studied how the absence of Treg cells during the second week of epicutaneous 
sensitization would modulate the subsequent airway inflammation (II, Fig. 6a). The 
inflammatory response in the lung of DEREG mice was significantly augmented, as 
evidenced by enhanced cellular infiltration into the lung (II, Fig. 6b), upregulated 
expression of IL-4 (II, Fig. 6c) and increased eosinophilia and T cell infiltration in the 
BAL fluid (II, Fig. 6d). By the time of read-out, the ratio of Foxp3+ cells in the LNs had 
already been restored, but the value was lower in the BALF (II, Fig. 6e). 
8.3 Role of Foxp3+ Treg cells during different phases of 
experimental CHS (III) 
Previous experiments have demonstrated a role for Foxp3+ Treg cells in the control of 
CHS responses during both sensitization and elicitation phases (Honda et al., 2011; 
Tomura et al., 2010). Moreover, Foxp3 Treg+ cells are known to migrate into the skin 
during the resolution phase (Tomura et al., 2010). However, the relative importance of 
regulation during different phases and the site and mode of action are still unknown. The 
role of Foxp3+ Treg cells was studied in different phases of a CHS response by depleting 
Foxp3+ Treg cells with DT-treatment either one day prior to sensitization (sensDT) or one 
day prior to elicitation (elicDT) (III, Fig. 1a). At 24 hours post challenge, the percentage 
of Foxp3+ cells in the sensDT group was approximately two thirds of the WT level, while 
in the elicDT group, the CD4+Foxp3+ cells were almost completely absent. In the skin the 
percentages were much lower than in WT in both groups (III, Fig 1b, c). 
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Compared to WT, the ear swelling and infiltration of inflammatory cells were much more 
severe in sensDT DEREG mice (III, Fig. 2b, c) and the mRNA expressions of 
proinflammatory IL-6, Th1 cytokine IFN-γ and anti-inflammatory cytokine IL-10 were 
significantly increased (III, Fig. 2e). In addition, the mRNA expressions of CXCL9 and 
CXCL10, which are involved in T cell recruitment into the skin during CHS responses, 
were significantly upregulated (III, Fig. 2f). Instead, in the elicDT DEREG mice, the ear 
swelling response, cellular infiltrate and the expression of inflammatory cytokines was 
comparable with the WT at 24 hours post elicitation (III, Fig. 3).  
 
The effects of Treg depletion on the phenotype of Teff cells and DCs were studied. The 
percentage of proliferating CD4+ and CD8+ T cells and activated Teff cells, as assessed 
by the expression of CTLA-4 (Valk et al., 2008), was significantly increased in the LNs of 
sensDT DEREG mice but not in elicDT DEREG mice compared with WT (III, Fig. 4a, b). 
Also, the expression of costimulatory molecules CD80 and CD86 on DCs was upregulated 
in sensDT group, both in the LNs and in the skin (III, Fig. 5). Again, no difference was 
observed between WT and elicDT DEREG mice. 
 
In order to avoid excessive tissue damage, the CHS response needs to be downregulated 
within a few days after exposure (Vocanson et al., 2009). The inflammatory response was 
followed for 96 hours after the challenge, and it was observed that ear swelling and 
expression of inflammatory cytokines were downregulated in the WT mice already at 48 
hours (III, Fig. 6a, c). The downregulation was accompanied by a gradual increase in the 
percentages of Foxp3+ Treg cell numbers in the skin, reaching as high as 50 % of CD4+ T 
cells at 96 hours post challenge. In contrast, in the dLNs, the percentage of Foxp3+ Treg 
cells remained constant (III, Fig. 6b). In sensDT DEREG mice, the inflammatory response 
was prolonged (III, Fig. 6a, c, d) and while the percentage of Foxp3+ cells in the dLNs of 
sensDT DEREG mice reached a similar level with WT by 96 hours post challenge, in the 
skin the percentage remained low, being only 15 % (III, Fig. 6b). In the elicDT group, the 
inflammatory response was also prolonged (III, Fig. 6a, c, d) and the percentage of 
Foxp3+ Treg cells was low both in the dLNs and the skin (III, Fig. 6b). 
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8.4 Effects of CCR4 deficiency in experimental CHS (IV) 
CCR4 is a chemokine receptor which is important for effector T cell recruitment into the 
skin (Campbell et al., 2007; Reiss et al., 2001). In addition, CCR4 has a crucial role in the 
function of Treg cells (Baatar et al., 2007; Iellem et al., 2001; Yuan et al., 2007) and is 
essential for Treg cell recruitment into the skin in the steady state (Sather et al., 2007). A 
CCR4 knock-out mouse was utilized to study the effects of CCR4 deficiency on the 
inflammatory response during oxazolone induced CHS. 
 
Compared to their WT littermates, CCR4-/- mice developed slightly but significantly 
exacerbated skin inflammation after oxazolone (OXA) sensitization and challenge. The 
ear swelling response was significantly increased in CCR4-/- mice as was the total number 
of inflammatory cells in the skin (IV, Fig 1). The IHC staining and flow cytometric 
analysis revealed an increased CD4+/CD8+ ratio in the skin (IV, Fig. 2). To further 
examine the CD4/CD8 T cell ratio, the numbers of CD4+ and CD8+ T cells in the dLN 
were followed on days 0, 2, 4 and 7 after oxazolone sensitization and 0, 4, 12 and 24 hours 
post challenge. The number of CD3+CD4+ cells in the draining LNs was higher in   
CCR4-/- mice at 7 days post sensitization as compared with WT (IV, Fig. 6a). In addition, 
already at 4 hours post challenge the numbers of CD4+ T cells in the LNs of CCR4-/- 
mice were significantly increased as compared to WT (IV, Fig. 6b). Instead, the number of 
CD8+ T cells was equal to WT at all time points studied (IV, Fig. 6a and b).  
 
The mRNA analysis of the exposed skin demonstrated significantly increased expression 
of several cytokines such as IL-6, TNF-α, IL-12p35, IL-4 and IL-13 in the skin of    
CCR4-/- mice (IV, Fig. 3a and b). However, the flow cytometric analysis of the skin 
revealed similar percentages of IL-13 and IFN-γ producing cells in the skin (IV, Fig. 3c) 
indicating that increased IL-13 mRNA levels in the skin had resulted from increased 
numbers of T cells in the skin. In support of this finding, stimulation of LN cells ex vivo at 
different time points after challenge revealed increased numbers of IL-13 producing cells 
in CCR4-/- mice whereas the numbers producing IFN-γ were at similar level with the WT 
(IV, Fig. 7 a, b). 
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Enhanced cellular recruitment may also result in increased cell numbers in the skin, which 
led us to analyze the expression of adhesion molecules E- and P-selectin in the skin. The 
expression levels of both these selectins were upregulated in CCR4-/- mice compared with 
WT (IV, Fig. 4a). In addition, the mRNA expression levels of chemokines CCL3, CCL4, 
CCL5 and CCL8 together with corresponding receptors CCR5 and CCR3 were increased 
in CCR4-/- mice (IV, Fig. 4b and c).  
 
CCR10, which is another skin homing receptor responding to chemokine CCL27 (Homey 
et al., 2000), was expressed at a similar level in WT and CCR4-/- mice as demonstrated by 
mRNA and flow cytometric analysis of the skin (IV, Fig. 5a, b). In addition, the 
chemotactic response towards CCL27 was equal in WT and CCR4-/- mice (IV, Fig. 5c). 
 
The mRNA expression of Foxp3 was increased in the skin in CCR4-/- mice and this result 
was further confirmed with flow cytometry and IHC staining (IV, Fig. 8a, b).The number 
of Foxp+ cells in the draining lymph node followed the kinetics of CD3+CD4+ cells (IV, 
Fig. 8c). The mRNA expression of anti-inflammatory cytokine TGF-β was upregulated in 
CCR4-/- mice whereas IL-10 expression was similar to that detected in WT (IV, Fig. 8a). 
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9. Discussion 
The occurrence of allergic diseases has been increasing for several decades and although 
the increase may have plateaued in some industrialized countries, the incidence rate is still 
high and the prevalence is rapidly increasing in the developing countries (Williams et al., 
2008). In the future, successful treatment of allergic diseases must be accompanied with 
an effective means of prevention of these diseases. In this thesis, mechanisms involved in 
allergic skin diseases were studied.  
 
In a murine model of AD, the S. aureus derived enterotoxin B (SEB) enhanced allergic 
inflammation and additionally induced mixed Th2/Th1 type inflammatory response, 
indicating that S. aureus colonization in the skin of AD patients may play a significant 
role in the exacerbation and chronification of this disease. Similarly, the depletion of Treg 
cells during epicutaneous sensitization phase augmented the inflammatory response in 
AD, clarifying the previously controversial role of Foxp3+ Treg cells in this disease. In 
addition, the absence of functional Treg cells during skin sensitization had long lasting 
effects on the subsequent airway inflammation.  
 
In CHS, a transient depletion of Treg cells during the sensitization, elicitation or resolution 
phase, revealed important role for Foxp3+ Treg cells especially in the control of priming 
of naive T cells as well as the resolution of inflammation. Instead, Foxp3+ Treg cells seem 
dispensable during the early phases of secondary responses. Finally, the absence of the 
skin homing receptor CCR4 lead to an unexpected worsened skin inflammation with 
altered CD4/CD8 balance, sustained high CD4+ cell numbers during sensitization phase 
and more rapid proliferation of CD4+ cells during the elicitation phase, indicating that 
CCR4 is in some way involved in the regulatory mechanisms during a CHS response.  
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9.1 SEB exposure induces infiltration of CD8+ T cells and 
mixed Th1/Th2-type dermatitis (I) 
An inherited defect in the production of antimicrobial peptides may account for enhanced 
susceptibility to suffer bacterial infections in AD patients (Nomura et al., 2003; Ong et al., 
2002). In addition, the Th2 dominated cytokine milieu in AD skin may decrease the 
production of AMPs (Howell et al., 2006). Bacterial colonization can exacerbate the skin 
inflammation in AD patients e.g. by producing microbial toxins which can activate the 
immune system through several mechanisms. S. aureus can produce a plethora of different 
toxins, many of which can act as superantigens (Fraser and Proft, 2008). Since 
sensitization to SEB has been shown to correlate with the severity of AD lesions (Breuer 
et al., 2000), it was decided to examine the effects of SEB on the inflammatory response 
in the murine model of AD.  
 
The skin of AD patients as well as OVA sensitized mice is occupied mainly by CD4+ T 
cells and only a few CD8+ T cells have been found in the epidermis (Lugovic et al., 
2005). In the present experiments, SEB exposure induced a marked infiltration of CD8 T 
cells, especially of the Vβ8+ subtype, into the skin. This result is in line with previous 
experiments which have demonstrated that Vβ8+ T cells are the major T cell type 
responding to SEB (Marrack and Kappler, 1990) and that cutaneous SEB exposure 
provokes inflammatory responses mediated by Vβ8+ T cells (Saloga et al., 1996). 
Previously it has also been reported that CD8+ T cells derived from lesional AD skin or 
blood of AD patients, efficiently proliferate after superantigenic stimulation (Akdis et al., 
1999). These results suggest that bacterial toxins secreted by skin colonizing bacteria in 
AD patients may lead to accumulation and activation of CD8+ T cells in the skin and 
subsequently affect the inflammatory response in AD.  
 
Epicutaneous sensitization with SEB alone induced an allergic inflammation in the skin as 
evidenced by the expression of Th2 type cytokines and production of SEB-specific IgE 
antibodies. These results are in accordance with previous studies (Laouini et al., 2003; 
Saloga et al., 1996; Skov et al., 2000) and indicate that SEB is able to act as a 
conventional allergen. Simultaneous application of SEB together with OVA exacerbated 
the OVA induced allergic skin inflammation. The cellular infiltration and production of 
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Th2 cytokines and OVA-specific antibodies were increased. In addition, the expression of 
Th1 cytokines in the skin was induced after SEB exposure, resulting in a mixed Th1/Th2 
type inflammation in SEB and SEB/OVA exposed mice. 
 
SEB stimulation elicited a strong IFN-γ production in the LN cells derived from SEB and 
SEB/OVA exposed mice, but not from OVA or PBS sensitized mice, pointing to the 
presence of SEB-specific cells. They were most likely CD8 cells, since the number of 
CD8 cells was increased in SEB and SEB/OVA treated group, whereas elevated CD4+ T 
cell numbers were observed only in SEB treated group. In addition, a previous experiment 
has demonstrated a strong IFN-γ production from CD8+Vβ8+ cells in SEB-injected mice 
(Herrmann et al., 1992). In an attempt to further elucidate the cellular recruitment into the 
skin, it was decided to investigate the expression levels of several chemokines. 
Simultaneous application of SEB and OVA synergistically elevated the expression levels 
of several proinflammatory chemokines. In addition, SEB treatment increased OVA 
induced expression of Th2 type chemokines and provoked the expression of Th1 
chemokines, indicating not only an enhanced recruitment of Th2 type cells but also active 
recruitment of Th1 cells to the site of inflammation after SEB exposure. In conclusion, 
these results indicate that SEB exposure might play a role in the chronification of the AD-
like inflammation. 
 
As a conclusion, these results demonstrate that toxins produced by skin colonizing 
bacteria may contribute both to the disease severity in AD patients as well as to 
chronification of the AD lesions. Therefore, careful control of S. aureus colonization on 
the skin of AD patients is crucial for treatment of AD. 
9.2 Foxp3+ cells control inflammatory responses during 
allergic skin inflammation (II and III) 
At present, the role of Foxp3+ cells in the pathomechanisms of AD is unclear. Studies on 
lesional skin of AD patients have revealed either the presence or absence of Foxp3+ cells 
(Schnopp et al., 2007; Szegedi et al., 2009; Verhagen et al., 2006) and while some 
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experiments report increased numbers of CD4+CD25+Foxp3+ cells in the blood of AD 
patients, some experiments show no differences but instead report increased numbers of 
Foxp3- Tr1 cells in AD patients compared to healthy controls (Ito et al., 2009; Ou et al., 
2004; Reefer et al., 2008; Szegedi et al., 2009). It was thus decided to examine the role of 
Foxp3+ Treg cells during AD-like inflammation. 
 
After repeated epicutaenous OVA exposure, the number of Foxp3+ cells significantly 
increased in the skin and LNs. However, the ratio of Foxp3+ T cells to Foxp3- T cells both 
in the skin and LNs remained unchanged, suggesting maintenance of Treg-Teff 
homeostasis even during inflammation. CD103+ has been reported to act as a marker for 
effector/memory type Treg cell in mice and it has been shown to play a role in the 
retention of Treg cells at the site of inflammation (Huehn et al., 2004; Siegmund et al., 
2005; Suffia et al., 2005). The steady increase of CD103+ Treg cells observed during 
exposure protocol indicated an active role for Treg cells during AD-like skin 
inflammation. Indeed, although showing a slightly impaired ability to suppress Teff cell 
proliferation under Th2 environment, the almost complete obliteration of Foxp3+ Treg 
cells during the second sensitization week severely augmented the inflammatory response 
in DEREG mice compared with WT mice.  
 
Tape stripping alone induced a mild skin inflammation in the PBS irritation WT controls 
and a much stronger response in the DT treated DEREG mice. The purpose of the tape 
stripping is to mimic the impaired skin barrier function that is encountered in AD patients 
(Kim et al., 2008; Marenholz et al., 2006; Palmer et al., 2006). The skin injury facilitates 
the penetration of the allergen through the skin and is essential for achieving proper 
sensitization. Tape stripping combined with OVA exposure further exacerbated the 
inflammatory response, resulting in significantly increased cellular infiltration, activation 
of Th2 cells and strongly elevated production of OVA-specific IgE, and more in DEREG 
than in WT mice. Importantly, depleting naive DEREG mice of their Treg cell 
compartment had no effect on the skin, proving that the exaggerated skin inflammation in 
the DEREG mice is not simply a consequence of the deletion of Treg cells. These results 
clearly demonstrate that Treg cells are crucial in controlling both the skin injury induced 
inflammation and the antigen-specific Th2 responses, both of which are essential 
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components of AD-associated pathology. It is noteworthy that the expression of the 
immunosuppressive cytokine, IL-10, was significantly elevated in DT treated OVA 
DEREG mice, indicating Foxp3+ Treg cell independent IL-10 production in the skin. 
Macrophages, DCs, and neutrophils among with keratinocytes and other skin cells are all 
significant producers of IL-10 (Wills-Karp et al., 2001; Vocanson et al., 2009). In 
addition, a contribution of Foxp3- IL-10+ Tr1 cells cannot be excluded (Hawrylowicz and 
O'Garra, 2005). A greater proportion of Foxp3- T cells in DEREG mice expressed PD-1 
compared with WT, which may point to the presence of a higher number of Foxp3- iTreg 
cells in DEREG mice. 
 
Depletion of Treg cells during skin sensitization had long-lasting consequences. The 
airway challenge one week after the end of the AD protocol induced inflammation in the 
lungs that reflected the situation in the skin, although the Foxp3+ Treg cell number had 
already been restored in the LNs. The total infiltration of cells was increased, especially in 
the lung parenchyma and increased numbers of CD4+ T cells was observed in the BALF. 
Moreover, the mRNA expression of IL-4 was significantly upregulated. This observation 
suggests that during the skin sensitization phase, dysfunctional/underactivated Foxp3+ 
Treg cells, e.g. due to decreased microbial burden or inherited Th2 biased immune 
responses, may modify the outcome of asthma response possibly developing later in AD 
patients. 
 
In CHS, Treg cells have been shown to have a role in all three phases of a CHS response, 
the sensitization, the elicitation and the resolution phase (Honda et al., 2011; Kish et al., 
2005; Ring et al., 2009; Tomura et al., 2010). However, the relative importance of Treg 
activities as well as the site and mode of Treg action during these phases is unclear. In our 
experiments, mice were depleted of Foxp3+ Treg cells one day prior to sensitization or 
one day prior to elicitation, and the inflammatory response was followed at 24-96h post 
elicitation. At 24 hour post challenge, mice depleted of Foxp3+ cells one day prior to 
sensitization showed significantly increased ear swelling, infiltration of inflammatory cells 
and production of several inflammatory cytokines and chemokines compared with WT. 
Conversely, in mice depleted one day prior to elicitation, the inflammatory parameters 
were at a similar level with WT. Similar kinds of results have been obtained in mice 
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injected with anti-CTLA-4 (Nuriya et al., 2001), which is one of the central mechanisms 
of Treg mediated suppression (Wing and Sakaguchi, 2010). These results suggest that 
Foxp3+ Treg cells are especially important during priming, but seem to be redundant 
during the first 24 hours after challenge.  
 
When the inflammatory response was followed beyond 24 hour time point, the 
inflammatory response in sensDT DEREG mice was sustained at a higher level compared 
to WT still at 96 hours after elicitation. This is in accordance with the experiments 
reported by Kish et al. (2005) and Honda et al. (2011), who demonstrated that depletion of 
CD25+ Treg cells or Foxp3+ Treg cells, respectively, at the sensitization phase results in 
exaggerated and prolonged inflammation. In elicDT mice, the ear swelling also continued 
to increase and the expression of inflammatory cytokines was upregulated compared to 
WT. Similar kind of observations were made also by Tomura et al.(2010) in CHS 
experiments with DNFB, which suggest that Foxp3+ Treg cells are essential in 
terminating the CHS response. 
 
The site of action of Foxp3+ Treg cells during challenge phase is not clear. Tomura et al. 
(2010) demonstrated that Foxp3+ Treg cells continuously migrate from the skin into the 
LNs and back to the skin during cutaneous immune responses. These Treg cells were 
highly immunosuppressive and were able to downregulate ear swelling responses. It was 
decided to follow Foxp3+ Treg percentages both in the dLNs and the skin at different time 
points after challenge. In the dLNs of WT mice, the ratio of Foxp3+ cells remained similar 
throughout the observation period. Instead, in the skin, the proportion of Foxp3+ cells 
significantly increased as a function of time, reaching as high as 50 % of CD3+CD4+ cells 
at the 96 hour time point. The strength of inflammation inversely correlated with the 
percentage of Foxp3+ Treg cells. In contrast, in sensDT mice, the proportion of Foxp3+ 
cells in the skin was significantly lower compared to WT although Treg/Teff balance had 
been restored in the LNs. At the same time, the inflammatory response in the skin was 
sustained at higher level compared to WT. These results point to an active role for Foxp3+ 
Treg cells in the skin during the resolution phase.  
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A similar kind of situation was observed also in the lungs in the AD-asthma study where 
Foxp3+ Treg percentages in DEREG mice were even higher in the LNs compared to WT, 
but remained significantly lower in the lungs. For some reason, restored Foxp3+ Treg cells 
do not accumulate at the site of inflammation. One possibility is the lack of antigen-
specific Foxp3+ Treg cells due to depletion, and subsequent impaired activation and/or 
migration of Foxp3+ cells into the inflammatory site. However, this phenomenon cannot 
explain the reduced Foxp3+ cell ratios in the lungs of PBS treated mice since these mice 
have never received OVA and therefore recruitment of Foxp3+ cells cannot be dependent 
on the presence of the antigen. However, it is possible that intranasal administration 
causes cellular damage which results in the release of self-antigens, and possibly the 
recruitment of nTreg cells into the lungs. A greater percentage Foxp3+ cells in DEREG 
mice after DT treatment stained positive for PD-1 as compared with WT, indicating that a 
larger share of the remaining/restored Foxp3+ cells in DEREG mice are iTreg cells 
(Haribhai et al., 2011) which may not react as readily to self-antigens as their nTreg cell 
counterparts (Belkaid, 2007). This could be one explanation for the decline in Foxp3+ cell 
numbers in the BAL-fluid of PBS treated DEREG mice. However, a more probable 
explanation is that it requires a longer time for Foxp3+ cells to recover in the periphery 
than in lymphoid organs. Further studies are needed to clarify this issue, but it seems that 
once Foxp3+ cells do not accumulate at the site of inflammation, the inflammatory 
response is stronger and/or prolonged. 
 
Treg cells utilize numerous mechanisms for the suppression of inflammatory responses. 
Some of them are targeted directly at Teff cells or indirectly via DCs. In order to 
characterize the important mechanisms utilized by Treg cells during allergic skin 
inflammation, the proliferation and activation status of Teff cells and DCs were studied 
both in AD and CHS. In both experiments, the percentage of proliferating, Ki67+, T cells 
in the dLNs were significantly increased, both in CD4 and CD8 subtypes, when allergen 
exposure occurred in the absence of Treg cells for several days. However, if only a short 
period of time had passed since Treg depletion, such as 24 hours in the challenge phase of 
CHS, no differences were observed in the numbers of proliferating cells between WT and 
DEREG mice. Similarly, the number of activated T cells, as evaluated by the percentage 
of CD69+ (AD) or CTLA-4+ (CHS) cells, was increased in those mice where a few days 
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had elapsed after Treg depletion. These results indicate that during allergic skin 
inflammation the control of T cell division and suppression of Teff activation are 
important means of suppression, but take several days to exert a visible impact. 
 
The percentages of CD80+ and CD86+ DCs were increased in the LNs of DEREG mice, 
again after several days of Foxp3+ Treg depletion. Additionally, in the skin, the mRNAs 
for CD80 and CD86 were significantly upregulated in DEREG mice, both in AD and 
CHS. In AD, increased percentages of DCs were positive for Ki-67 and there were 
increased numbers of CD11b+ DCs, which may indicate a presence of inflammation 
related IDEC cells (Kerschenlohr et al., 2003; Schuller et al., 2001). Together these results 
demonstrate that also DCs are targets of Treg mediated suppression during allergic skin 
inflammation.  
 
These results emphasize the importance of functional Foxp3+ Treg cells especially during 
priming of T cells, since the absence of Foxp3+ Treg cells at this stage has long-lasting 
effects on memory responses which cannot be reversed by restoration of Foxp3+ Treg 
population. Instead, during the rapid recall response, Treg cells are redundant, but their 
presence at the site of inflammation during memory response seems to be essential for the 
control and clearance of the inflammatory response. 
 
9.3 Exacerbated inflammatory response in CCR4-/- mice (IV) 
Some experiments have demonstrated that either CCR4 or CCR10 alone is essential for 
skin homing of T cells during inflammation (Campbell et al., 2007; Homey et al., 2002), 
whereas others have claimed that CCR4 and CCR10 possess overlapping roles, and only 
simultaneous blockade of both receptors diminishes cellular infiltration into the skin 
(Mirshahpanah et al., 2008; Reiss et al., 2001; Wang et al., 2009b). Most likely the 
importance of a particular receptor is related to the inflammatory conditions, which in turn 
are affected by the model or the antigen used. For example in mice, administration of α-
CCL17/α-CCL22 alone or together with α-CCL27 had variable effects on the extent of 
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infiltration by inflammatory cells when different chemicals (DNFB, OXA or TMA) were 
used (Mirshahpanah et al., 2008).  
 
When the effects of oxazolone induced skin inflammation were investigated in   CCR4-/- 
knock-out mice, it was observed that there was an augmented inflammatory response 
compared with WT. The ear swelling response was enhanced due to edema and increased 
cellular infiltration. Additionally, the mRNA expression of various inflammatory 
cytokines and chemokines was significantly increased. Similar kinds of results have been 
obtained by Reiss et al. (2001) who observed that the ear swelling responses in DNFB 
sensitized and challenged CCR4-/- mice were slightly increased compared with WT. In 
addition, in an adoptive transfer model, it was noticed that CCR4-/- T cells accumulated in 
the skin at least as well as WT cells (Reiss et al., 2001).  
 
Since CCR10 might compensate for the lack of CCR4 in some inflammatory situations, 
CCR10 expression was studied in CCR4-/- T cells compared with WT. The same 
percentage of skin derived T cells stained positive for CCR10 (17.2 % in WT vs. 19.4 % 
in CCR4-/-) and the mRNA levels of CCR10 in the skin were similar between WT and 
CCR4-/- mice. In addition, the chemotactic response towards CCR10 ligand, CCL27, was 
comparable with the WT, suggesting a functional but not overly activated CCL27-CCR10 
pathway in CCR4-/- mice. 
 
Instead, the mRNA expressions of E- and P-selectins, important adhesion molecules for 
tethering and rolling (Harari et al., 1999), were upregulated in CCR4-/- mice. This 
upregulated selectin expression together with increased mRNA expression of several 
chemokines and corresponding receptors, indicates more efficient recruitment of 
inflammatory cells into the skin of CCR4-/- mice. 
 
In an attempt to further understand the enhanced inflammation in CCR4-/- mice, the 
immune responses were monitored at various time points after sensitization and 
elicitation. There were significantly increased CD4+ cell numbers compared with WT, 
first at the LNs at the end of the sensitization period, next in the LNs at 4 and 12 hours 
post challenge and finally in the skin at 24 hours post challenge. Enhanced proliferation of 
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CCR4 deficient CD4+ T cells was also observed by Campbell et al. (2007) in the dLNs 
upon antigen stimulation, although the difference did not reach statistical significance in 
their experiment. Nonetheless, these results suggest a small but persistent role for CCR4 in 
the control of CD4+ T cell division. These more rapidly dividing cells were most likely 
Th2 cells, since the numbers of IL-13 producing cells in the LNs followed the kinetics of 
CD4+ cells and were significantly increased in CCR4-/- mice compared to WT.  
 
The faster proliferation of CD4+ Th2 cells, together with upregulated selectin and 
chemokine expression, most likely resulted in the increased cellular infiltration in CCR4-/- 
mice and consequently to the expression of elevated levels of inflammatory cytokines and 
enhanced inflammation. The reason for this enhanced proliferation and recruitment, 
however, is still not known. CCR4 is expressed by the majority of Treg cells (Iellem et al., 
2001) and it has been reported to play essential roles in their function. For example, it has 
been reported that cardiac allograft tolerance is mediated by Treg cells and is dependent 
on CCR4 expression (Lee et al., 2005). CCR4 is also involved in the interaction between 
DCs and Treg cells and the production of immunosuppressive IDO from DCs (Onodera et 
al., 2009). In mice, the absence of CCR4 on Treg cells results in a spontaneous skin 
inflammation, most likely due to impaired homing of Treg cells into the skin (Sather et al., 
2007). However, in the present experiments, Foxp3+ cells in CCR4-/- mice were equally 
well recruited into the skin as in WT mice and the percentage of Foxp3+ cells in the 
draining lymph nodes during the sensitization and elicitation phase was similar in both 
groups. These results demonstrate that although necessary for the steady state recruitment 
of Treg cells into the skin, CCR4 is not essential for Treg cell accumulation during 
inflammation.  
 
It cannot be ruled out, however, that the function of Treg cells was slightly impaired in 
CCR4-/- mice. Treg cells are known to interfere with Teff-DC interactions by forming 
contacts with antigen-bearing DCs (Tadokoro et al., 2006; Tang et al., 2006). Activated 
DCs produce CCL22 (Onodera et al., 2009; Tang and Cyster, 1999; Vulcano et al., 2001) 
and for example, in a mouse model of inflammatory bowel disease, CCR4 deficiency 
resulted in the generation of pathogenic T cells, most likely due to impaired Treg-DC 
interactions (Yuan et al., 2007). A similar situation could apply in the present CHS 
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experiment with CCR4-/- mice and result in increased proliferation of CD4+ T cells. 
Furthermore, Ring et al. (2009) have demonstrated that Treg cells control the expression 
of P-and E-selectins in the endothelium and impaired function of Treg cells could explain 
the increased E-and P-selectin expression observed in our study. As shown by experiments 
by us and others (Honda et al., 2011; Kish et al., 2005), the absence of functional Treg 
cells during sensitization phase results in augmented secondary response. Although the 
inflammatory response in CCR4-/- mice was not as drastically exacerbated as in Treg 
depletion studies, the results could indicate a slight impairment of Treg function. 
However, further studies are needed to clarify these issues.  
 
9.4 Future directions 
Superantigens can exacerbate skin inflammation through several mechanisms, one being 
an ability to impair the suppressive function of Treg cells (Cardona et al., 2006; Lin et al., 
2011). As shown by our Treg depletion studies with the AD model, the absence of 
functional Treg cells resulted in a strongly enhanced inflammatory response with elevated 
IFN-γ, IL-4 and IL-13 production and increased serum IgE and IgG2a levels. In addition, 
the number of T cells was elevated in the skin while the number of eosinophils was not 
affected. As SEB exposure together with OVA sensitization induced similar kinds of 
changes in the inflammatory responses, it is possible that impairment of Treg function is 
one of the mechanisms through which SEB augments AD-like skin inflammation. This 
should be studied in the future. In addition, Th2 cytokines have been shown to suppress 
the production of antimicrobial peptides (Howell et al., 2006) and a previous study 
demonstrated lowered amounts of cathelicidin-related antimicrobial peptide in the skin of 
mice sensitized epicutaneously with OVA (Scott et al., 2007). Since at least 20 different 
AMPs have been recognized in the skin (Braff and Gallo, 2006), it would be interesting to 
study how their production is modulated in the skin after OVA-sensitization.  
 
Our results suggest that Foxp3+ Treg function is important in the LNs during priming. 
However, different sites of action during the secondary response have been proposed 
(Ring et al., 2010; Tomura et al., 2010). Our results show that at different time points after 
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elicitation, the ratios of Foxp3+ Treg cells were lower in DEREG mice at the site of 
inflammation, i.e. in the lungs or skin, while their number was restored in the LNs, 
suggesting that the Foxp3+ Treg/Teff cell ratio might be of relevance at the site of allergen 
exposure in the sensitized individual. For example in the future, it would be interesting to 
study with the help of knock-out mice with deficiencies in different homing receptors, if 
the presence of Foxp3+ Treg cells during secondary response is especially important at the 
site of inflammation, in the blood vessels lining the site of inflammation or in the draining 
LNs. It would also be of interest to study if the lowered Treg ratio is due to a lack of 
antigen specificity after Foxp3+ Treg depletion or does the restoration of Treg numbers in 
the periphery take a longer time than in the secondary lymphoid tissues. In addition, 
studies investigating the possible mechanisms of suppression by Treg cells during these 
inflammatory processes would be worthwhile in order to understand which molecules are 
important for interaction between Treg cells, Teff cells and DCs during allergic skin 
inflammation. In addition, in vivo activation of Treg cells through administration of 
probiotics or in vitro expansion of antigen-specific Treg cells would be interesting topics 
for future studies.  
 
In CCR4 experiments, the functionality of CCR4-/- Treg cells should be assessed. 
Although previous attempts have found no impaired ability of CCR4-/- cells to suppress T 
cell proliferation in vitro (Yuan et al., 2007), the effect of CCR4 deficiency might be 
different in vivo, where the expression of chemokine receptor might be more important for 
migration and/or retention of the cells in the LNs or at the site of inflammation than in a 
Petri-dish where cells exist in close contact with each other. In addition, inhibition of 
proliferation is only one mechanism of suppression and therefore the activation status and 
cytokine production of Teff cells and DCs should also be studied. The drawback in our 
experiments was that CCR4 was absent from all cell types, also from Teff cells. Since 
CCR4 has been proven to be important for Teff cell/DC interactions as well as Treg/DC 
interactions, it would be interesting to study if it is even more important for Treg cells than 
Teff cells since clearly Teff cells were able to become activated in the absence of CCR4. 
Injection of WT or CCR4-/- Treg cells into DEREG mice depleted of Treg cells in the 
CHS model, could help to clarify the role of CCR4 in Treg cell function during CHS. 
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10. Conclusions 
 
 
This thesis has attempted to unravel some of the issues involved in the pathomechanisms 
of allergic skin diseases. S. aureus colonization is a severe problem for AD patients and it 
was possible to prove experimentally that S. aureus derived enterotoxin B considerably 
exacerbated the allergic skin inflammation induced by OVA and could also act as an 
allergen itself. In addition, SEB enhanced the allergic response also systemically as 
demonstrated by elevated allergen- and SEB-specific IgE levels. Furthermore, SEB 
increased the production of Th2 cytokines and also induced the production of Th1 type 
cytokines, normally observed in chronic AD lesions, suggesting that bacterial colonization 
on the skin may significantly contribute not only to the severity but also to the 
chronification of AD. Therefore, prevention of bacterial colonization deserves special 
attention when designing treatment strategies for AD.  
 
The role of Foxp3+ Treg cells in AD has been controversial. It was found that these cells 
play an indispensable role in the control of AD-like skin inflammation since depletion of 
Foxp3+ cells resulted in a significantly augmented inflammatory response with elevated 
expression of Th2 cytokines and enhanced production of IgE. It was further demonstrated 
that the absence of functional Foxp3+ Treg cells during skin sensitization affected the 
magnitude of inflammation upon subsequent airway challenge with the same antigen, 
despite the restored Foxp3+ Treg cell compartment. These results emphasize that the 
presence of active, functional Foxp3+ Treg cells are crucial for controlling the magnitude 
of skin inflammation and their absence during sensitization can have long-lasting 
consequences along the atopic march. 
 
In CHS, it was possible to demonstrate that the Foxp3 expressing Treg cells efficiently 
controlled the priming of naive T cells, but seemed to be redundant during the early 
inflammatory response after challenge. This result emphasizes the importance of the 
presence of functional, active Treg cells during the sensitization phase. In fact, functional 
Treg cells may prevent the sensitization against weak haptens altogether. This result is in 
line with the hygiene hypothesis which states that inflammation activated Treg cells raise 
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the threshold for sensitization and therefore can prevent the development of allergic 
diseases. In addition to controlling the priming of naive T cells, the importance of Foxp3+ 
Treg cells became again evident during the resolution phase, where the prolonged 
inflammatory response was accompanied by an impaired ability of Foxp3+ Treg cells to 
accumulate in the skin. This result suggests that the action of Treg cells at the site of 
inflammation might be important for the clearance of the inflammation.  
 
Finally, it was demonstrated in the oxazolone induced CHS model that CCR4-/- mice 
exhibited more extensive inflammation in the skin as compared to WT, most likely 
through enhanced proliferation of Th2 cells and increased expression of adhesion 
molecules in the skin. These results indicate that CCR4 is involved in the regulation of 
these two events. However, recruitment of Treg cells into the skin was not impaired in 
CCR4-/- mice and Treg cells proliferated as efficiently in WT and CCR4-/- mice. These 
results do not rule out however, the possibility that the functionality of Treg cells in these 
mice is impaired.  
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